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Introduction 
 
Drug design is an iterative process which begins when a chemist identifies a compound that 
displays an interesting biological profile and ends when both the activity profile and the 
chemical synthesis of the new chemical entity are optimized. One of the basic tenets of 
medicinal chemistry is that biological activity is dependent on the three-dimensional 
placement of specific functional groups. Computational chemistry/molecular modeling is the 
science of representing molecular structures numerically and simulating their behavior with 
the equations of quantum and classical physics. Computational chemistry programs allow 
scientists to generate and present molecular data including geometries (bond lengths, bond 
angles, torsion angles), energies (heat of formation, activation energy, etc.), electronic 
properties (moments, charges, ionization potential, electron affinity), spectroscopic 
properties (vibrational modes, chemical shifts) and bulk properties (volumes, surface areas, 
diffusion, viscosity, etc.). Comparison to experimental data, where available, is also 
important to guide both laboratory and computational work. 
Virtual screening is the application of computational models to select or prioritize 
compounds for experimental screening. There are two broad categories of virtual screening 
techniques: ligand-based design and structure-based design.  
Ligand-based design methods capitalize on the fact that ligands similar to an active ligand 
are more likely to be active than random ligands. Ligand-based approaches commonly 
consider two- or three-dimensional chemistry, shape, electrostatic, and interaction points 
(e.g., pharmacophore points) to assess similarity. Structure-based design attempts to use the 
3D protein structure to predict which ligands will bind to the target. The amount and quality 
of information required to apply these techniques varies. Ligand similarity approaches 
require only a single active molecule. Ligand-based Quantitative Structure-Activity 
Relationship (QSAR) approaches require a number of active molecules spanning a wide 
range of activity against the target receptor. The quality of the QSAR model depends to a 
large extent on the quality of the activity data, so that reliable QSAR models are usually built 
based on carefully acquired binding or inhibition data. Structure-based approaches, of which 
the best known is docking, require a protein structure or homology model as starting point. 
Pharmacophore models that include receptor information require an experimental structure 
of the complex between an active molecule and its target protein. 
 
Homology Modeling 
Homology modeling is an increasingly efficient way to obtain useful information about the 
proteins of interest. For example, in designing mutants it can be  helpful to test hypotheses 
about a protein function, identifying active and binding sites, identifying, designing and 
improving ligands for a given binding site, modeling substrate specificity, predicting antigenic 
epitopes, simulating protein–protein docking, refining models based on NMR constraints and 
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rationalizing known experimental observations. This computational approach is based on the 
notion that primary structure of proteins is conseved, through evolution, to a lesser extent 
than the higher level structures (secondary, tertiary and quaternary). The aim of homology 
protein structure modeling is to build a three-dimensional (3D) model for a protein of 
unknown structure (the target) on the basis of sequence similarity to proteins of known 
structure (the templates).1–5 Two conditions must be met to build an useful model. First, the 
similarity between the target sequence and the template structure must be detectable. 
Second, a substantially correct alignment between the target sequence and the template 
structures must be calculated. The obtained structure can be structurally refined with 
different protocols such as energy minimization. Comparative modeling is possible because 
small changes in the protein sequence usually result in small changes in its 3D structure.6 
Although considerable progress has been made in ab initio protein structure prediction,7 
comparative protein structure modeling remains the most accurate prediction method. 
 
Molecular Dynamics 
Molecular Dynamic simulations describe the time evolution of a molecular system, e.g., a 
protein, by numerically solving Newton’s equations of motion for all atoms in the system. 
Molecular dynamics combines energy calculations from force field methodology with the 
laws of Newtonian mechanics. Such simulations can accurately describe the dynamics of 
biological relevant systems by using three approximations; (a) the Born-Oppenheimer 
approximation, where nuclear and electronic motions are decoupled, (b) the approximation 
that nuclei can be treated as classical particles, and (c) the use of an empirical force field to 
describe the interaction between particles. The simulation of a protein or nucleic acid 
requires the explicit spatial coordinates and initial velocities of every atom in such a 
molecule. While the initial velocities can be obtained from a Maxwell-Boltzmann distribution 
at given temperature, the spatial coordinates were obtained from structures stored in the 
Protein Data Bank8 or from homology models. In molecular dynamics, successive 
configurations of the system are generated by integrating Newton’s laws of motion 
(Equation 1). The result is a trajectory that specifies how the positions and velocities vary 
with time. 
iii amF  
Equation 1: Newton’s law of motion 
where iF  is the force exerted on particle i , im  is the mass of particle i  and ia  is the 
acceleration of particle i . 
The force can also be expressed as the gradient of the potential energy (Equation 2). 
VF ii  
Equation 2 
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Combining these two equations yields Equation 3. 
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Equation 3 
where V is the potential energy of the system. 
Newton’s equation of motion can then relate the derivative of the potential energy to the 
changes in position as a function of time. 
Numerous numerical algorithms have been developed for integrating the equations of 
motion: 
- Verlet algorithm  
- Leap-frog algorithm 
- Velocity Verlet  
- Beeman’s algorithm 
 
All the integration algorithms assume the positions, velocities, and accelerations can be 
approximated by a Taylor series expansion (Equation 4). 
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Equation 4 
Where x is the position, v is the velocity (the first derivative with respect to time), a is the 
acceleration (the second derivative with respect to time). 
The Verlet algorithm uses positions and accelerations at time t and the positions from time  
t-δt to calculate new positions at time t+δt. The Verlet algorithm uses no explicit velocities. 
The advantages of the Verlet algorithm are simplicity, but the algorithm is of moderate 
precision.  
In the Leap-frog algorithm, the velocities are first calculated at time t+1/2δt; these are used 
to calculate the positions, x, at time t+δt. In this way, the velocities leap over the positions, 
then the positions leap over the velocities. The advantage of this algorithm is that the 
velocities are explicitly calculated; however, the disadvantage is that they are not calculated 
at the same time as the positions. 
The velocity-Verlet integrator algorithm yields positions, velocities, and accelerations at time 
t. There is no compromise on precision. 
The Beeman’s algorithm is closely related to the Verlet one. The advantage of this algorithm 
is that it provides a more accurate expression for the velocities and a better energy 
4 
 
conservation. The disadvantage is that the more complex expressions make the calculation 
more expensive. 
 
Molecular Docking 
Molecular Docking is a method that predicts structure of the intermolecular complex formed 
between two or more molecules. Frequently it is used to predict binding orientation of drug 
candidates to their protein targets in order to predict affinity and activity. Prediction of the 
binding affinity will be useful when compounds are being synthesed whereby it is possible to 
predict the affinity of the desired compound towards a certain target (say a protein or DNA; 
with particular interest to stop the function of the enzyme/protein or to block certain 
reaction). 
The orientation of the ligand (small molecule or substrate protein) will be “fitted” to the 
receptor of interest using either two approaches: matching technique, and simulation 
processes. 
Molecular docking can be divided into two separate sections: 
1) Search algorithm – The algorithm should create an optimum number of 
configurations that include the experimentally determined binding modes. So the 
search space consists of all possible orientations and conformations of the protein 
paired with the ligand. In practice it is impossible to exhaustively explore the search 
space because this would involve enumerating all possible distortions of each 
molecule and all possible rotational and translational orientations of the ligand. 
2) Scoring Function – Mathematical methods used to predict the strength of the 
non-covalent interaction, called as binding affinity, between two molecules after they 
have been docked. Scoring functions have also been developed to predict the 
strength of other types of intermolecular interactions, for example between two 
proteins or between protein and DNA or protein and drug. These configurations are 
evaluated using scoring functions to distinguish the experimental binding modes 
from all other modes explored through the searching algorithm. 
In standard virtual docking studies, ligands are docked into the binding site of a receptor 
where the receptor is held rigid and the ligand is free to move. However, the assumption 
of a rigid receptor can give misleading results, since in reality many proteins alter their 
binding site to conform to the shape and binding mode of the ligand. These changes 
allow the receptor to alter its binding site so that it more closely conforms to the shape 
and binding mode of the ligand. This is often referred to as “induced fit”. 
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1. Hypoxia and cancer 
 
Tumorigenesis in human is a multistep process that involves the sequential acquisition of a 
number of genetic, epigenetic, or somatic alterations as a result of increasing genomic 
instability caused by defects in cell cycle checkpoint controls.9 These alternations enable 
cancer cells to acquire characteristics different from normal cells: resistance to growth 
inhibitory factors, proliferation in the absence of exogenous growth factors, evasion of 
apoptosis, limitless replication potential via the reactivation of telomerase, abnormal 
angiogenesis, evasion of destruction by the immune system, invasion and metastasis.10 In 
addition to the genetic, epigenetic, or somatic changes that occur in cancer, the tumor 
microenvironment is considered to be a critical factor in malignancy progression and 
metastasis, and it influences the response to conventional anti-tumor therapies.11 
As one of the most pervasive microenvironmental stresses and common features of solid 
tumors, hypoxia has been recognized as playing a key role in several cellular physiological 
processes, from cell proliferation, to cell survival, angiogenesis, metabolism and tumor 
progression and metastasis (Fig. 1). 
 
Fig. 1: The role of hypoxia in the hallmarks of human cancer. 
To survive and grow in this hypoxic microenvironment, tumor cells co-opt adaptive 
mechanisms to switch to a glycolytic metabolism, promote proliferation, become resistant to 
apoptosis, obtain unlimited replication potential and genomic instability, evade immune 
attack, induce angiogenesis, and migrate to less hypoxic areas of the body. 
Hypoxia can be divided into acute and chronic hypoxia. The acute variant is usually caused 
by a temporary disruption to the blood flow and does not last long. On the other hand, 
chronic hypoxia is durable and can have lasting effects.12 
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Hypoxic cells have been shown to be more resistant to radiotherapy and chemotherapy, and 
they usually have been associated with increased risk of invasion and metastasis, and a poor 
clinical prognosis of solid tumors.13 Therefore, since HIF-1 is a key regulator of the response 
of cells to oxygen deprivation and plays critical roles in the adaptation of tumor cells to a 
hypoxic microenvironment, HIF-1 inhibition is an attractive anticancer target. Knowledge of 
the mechanisms of action of all the actors in the hypoxic pathway is thus becoming a priority 
in identifying new agents capable of specifically targeting HIF-1. 
 
Mdm2 and HIF-1α interaction in tumor cells during hypoxia 
The importance of the HIF-1 response pathway in human tumorigenesis is underscored by 
the finding that HIF-1α is overexpressed in multiple human cancers, because tumor cells, 
unlike normal cells from the same tissue, are often chronically hypoxic.14 
In normal unstressed cells, p53 is a very unstable protein with a short half-life, which is 
present at very low cellular levels owing to continuous degradation largely mediated by 
Mdm2. In contrast, the p53 protein is stabilized, and its level increases in response to various 
stresses such as DNA damage and hypoxia.15,16 Mdm2 an p53 are linked to each other 
through an autoregulatory negative feedback loop aimed at maintaining low cellular p53 
levels in the absence of stress. Mdm2 inhibits p53 activity because it stimulates its 
degradation in the nucleus and the cytoplasm, blocks its transcriptional activity interfering 
with the ability of p53 to contact transcriptional coactivators such as p300/CBP, and 
promotes its nuclear export to the cytoplasm, where p53 is then degraded by cytoplasmic 
proteasomes.17 
Evidence for interaction between HIF-1 and p53 network is substantial,18–21 the precise 
mechanism by which HIF-1α regulates p53-mediated function remains unknown (Fig. 2). 
 
Fig. 2 
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Mdm2 may act as a bridge and mediate the indirect interaction between HIF-1α and p53 in 
cells. HIF-1α protects p53 from degradation mediated by Mdm2 and can abrogate p53 
transcriptional repression by Mdm2. Also, HIF-1α interacts with the wild-type p53 protein 
but not the tumor-derived p53 mutant form in cells.18 Since wild-type p53 protein is capable 
of inducing Mdm2 expression in cells, in contrast, because the tumor-derived p53 mutant is 
completely inactive in transcriptional activation of endogenous Mdm2, HIF-1α fails to 
interact with p53 since there is no (or very low levels) Mdm2 in cells expressing mutated 
p53. 
 
A3 adenosine receptor induces HIF-1α protein accumulation in hypoxia 
Purine nucleosides, such as adenosine, are critical mediators of physiological responses to 
acute and chronic hypoxia. Adenosine is the final metabolite in the stepwise 
dephosphorylation of ATP and it is produced and released in response to ischemia and 
hypoxia in the central nervous system.22 
There is a strong link between adenosine and hypoxia-related signaling. The expression 
levels of adenosine and adenosine receptors are regulated in conditions of cellular stress, 
and signal transduction increases via one or more of the adenosine receptors. Hypoxia 
apparently induces a program that shifts the tissue phenotype toward an increase in 
extracellular adenosine. In turn, adenosine receptor activation tends to limit the potential 
damage incurred by hypoxia. 
Adenosine modulates a variety of cellular functions through occupancy of four cell surface 
G-protein–coupled receptors, named A1, A2A, A2B, and A3.23,24 In particular, adenosine was 
found to exert its effects on cell proliferation, clone formation ability, UV resistance, and cell 
death mainly through the A3 subtype,25–28 which is highly expressed in tumor cells.29–33 
These findings confirm recent data indicating that A3 receptor overexpression may be a 
good candidate as a tumor cell marker. 
Several reports demonstrate that adenosine is able to increase HIF-1α protein expression in 
response to hypoxia in a dose-dependent and time-dependent manner in human melanoma 
cells, whereas HIF-1β protein levels are not affected. A3 receptor subtype mediates the 
observed adenosine effects on HIF-1α regulation in this cell line. The effects of adenosine on 
HIF-1α protein accumulation are not mediated by A1, A2A, or A2B receptors but through A3 
receptors.34 
So given the ability of A3 adenosine receptor antagonists to block HIF-1α protein expression 
accumulation in hypoxia, this pathway could be a new approach for the treatment of cancer, 
based on the cooperation between hypoxic and adenosine signals, that ultimately may lead 
to the increase in HIF-1–mediated effects in cancer cells. 
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2. HIF-1α 
 
HIF-1 is a heterodimer composed of HIF-1α and HIF-1β subunits.35 Whereas HIF-1β is 
constitutively expressed, HIF-1α expression is induced in hypoxic cells with an exponential 
increase in expression as cells are exposed to O2 concentrations of less than 6%. Two other 
homologues of the α subunit have been cloned (HIF-2α or EPAS-1 and HIF-3α), but there 
appears to be little redundancy in the hypoxic response. The three related forms of human 
HIF-α (HIF-1α, HIF-2α, and HIF-3α) are encoded by a distinct genetic locus. HIF-1α and HIF-2α 
possess similar domain structures that are regulated in a related manner by oxygen, 
although each isoform has distinct and separate roles. The role of HIF-3α is not fully 
understood, although a truncated form of murine HIF-3α, known as inhibitory Per/Arnt/Sim 
(PAS) domain protein (IPAS), has been found to act as an inhibitor of HIF via dimerization 
with HIF-β. HIF-1α is the best characterized and forms a heterodimer with the HIF-1β 
subunit, initially identified as the Aryl hydrocarbon Receptor Nuclear Translocator (ARNT). 
HIF-2α and 3α compete for binding to ARNT. These proteins belong to the basic 
helix-loop-helix (bHLH)–PER-ARNT-SIM (PAS) protein family (Fig. 3). 
 
Fig. 3: Domain structure and structural location of the post-translational modifications of HIF-1α and β. 
 
The bHLH and PAS motifs are required for dimerization while the downstream basic region 
affords specific binding to the HRE DNA sequence 5′-ACGTG-3′. The stability and subsequent 
transactivational function of the α subunit of HIF-1 is regulated by its post-translational 
modification, in particular hydroxylation and phosphorylation. The Oxygen-Dependent 
Degradation Domain (ODDD) of HIF-1α regulates its stability through the hydroxylation of 
proline 402 and 564 by Prolyl Hydroxylase Domain (PHD) proteins and the acetylation of 
lysine 532 by ARrest Defective-1 protein (ARD1), which favour binding to and subsequent 
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ubiquitination by the von Hippel-Lindau (VHL) E3 ligase complex. The α subunit contains two 
transactivation domains, the N- and C-terminal activation domains, respectively N-TAD and 
C-TAD, while the β subunit contains only one TAD. A number of co-activators including 
CBP/p300 have been identified to interact with the C-TAD and to enhance transactivation. 
HIF-1α is phosphorylated, and phosphorylation has been shown to enhance transcriptional 
activity though possibly through modification of co-activators. The transcriptional activity is 
negatively regulated by hydroxylation of asparagine 803 by the Factor Inhibiting HIF-1 (FIH-1) 
in the C-TAD which abrogates binding of the co-activator CBP/p300. S-nitrosation of cysteine 
800 increases interaction with CBP/p300 and enhances transactivation, while the 
transcriptional activity of both subunits appears to be negatively regulated by 
SUMOylation.36 
In normoxia, HIF-1α constitutively transcribed and translated, but immediately directed for 
degradation. This is achieved by the hydroxylation of proline residues (P402 and P564) by 
the three PHDs, which depend on oxygen, 2-oxoglutarate, Fe+2, and ascorbate as substrates 
and cofactors for their activity. Prolyl hydroxylation permits the binding of the von 
Hippel-Lindau protein (pVHL), a recognition component of the E3 ligase complex37–42 
together with elongin B, elongin C, cullin-2, and ring-box 1. This complex ubiquinates HIF-1α 
subunits and targets them for proteosomal degradation.43 In addition, a conserved 
asparagine residue undergoes hydroxylation, by Factor Inhibiting HIF (FIH), which blocks 
activation of HIF target genes, as well as having other functions. 
In addition to ubiquitin, there exist a number of related polypeptides which are covalently 
attached to target proteins and regulate their function.44 The Small Ubiquitin-like MOdifier 
(SUMO) is one of these polypeptides, but in contrast to ubiquitin, SUMO does not signal 
protein destruction but instead may even protect proteins from ubiquitination and influence 
intracellular localization and protein–protein interactions.45 A growing number of 
transcription factors including p53, heat shock transcription factor, c-Myb, GRIP1, Sp3 and 
AP-2 are being reported to undergo SUMO post-translational modification. Often this 
modification negatively regulates the transcriptional activity and this has been 
demonstrated for the β subunit of HIF-1.46 Under hypoxic conditions, prolyl hydroxylation of 
HIF-1α is blocked and acetylation is down-regulated, permitting thus HIF-1α protein 
stabilization. HIF-1α protein accumulates and translocates to the nucleus where is then free 
to bind with HIF-1β to form the HIF-1 transcription complex. The heterodimer can then bind 
to hypoxic response elements (HREs) in the promoters of a host of genes and activate 
expression of these genes (Fig. 4). 
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Fig. 4 
The HIF-1α protein is an excellent example of multiple post-translational modifications as 
switches in function. Hydroxylation by PHD proteins and acetylation by ARD1 protein 
increase interaction of HIF-1α with the E3 ligase pVHL complex which earmarks HIF-1α with 
ubiquitin. Hydroxylation by FIH-1 decreases the transacriptional activity as does modification 
with SUMO. HIF-1α is phosphorylated by Mitogen Activated Protein Kinase (MAPK) and 
phosphorylation increases transactivation as does S-nitrosation. 
 
Regulation of HIF-1α protein stability under hypoxia 
Hypoxia-inducible factor can be activated by physiological or pathological activation of 
growth factor and cell adhesion pathways. Growth-factor-induced activation of receptor 
tyrosine kinases (RTKs) leads to HIF-1α stabilization and activation. Activated RTKs interact 
with p85, the regulatory subunit of Phosphatidyl Inositol 3-Kinase (PI3K), which leads to its 
activation. Activated PI3K triggers a phosphorylation cascade that results in the 
phosphorylation/activation of AKT, a serine/ threonine kinase that promotes antiapoptotic 
and pro-survival responses of a cell.47 Activation of AKT has been shown to lead to an 
increase in HIF-1 protein translation by the AKT/FRAP/mTOR pathway.48,49 Activated RTKs 
also signal through the MAPK pathway, and phosphorylated p38 and 
extracellular-signal-regulated kinase 1/2 (ERK1/2) can further phosphorylate and activate 
HIF-1.50 Inhibition of ERK activity leads to inhibition of HIF activity without affecting HIF 
stabilization.51 In addition to growth factor–mediated RTK activation, the PI3K/AKT pathway 
is also activated by extracellular matrix (ECM) adhesion mediated by integrins.52 Integrin 
ligation causes an activation of the integrin-linked kinase (ILK) leading to increased HIF-1, as 
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well as increased VEGF production by the PI3K/AKT/FRAP/mTOR pathway.53 Additionally, 
activation of PI3K/AKT also leads to an increase in steady-state concentrations of heat shock 
proteins (HSP) 90 and 70, both of which interact with and stabilize HIF-1.54 p53 negatively 
modulates this process by inducing Mdm2, which can ubiquitinate and lead to HIF-1 
degradation by the proteasome pathway (Fig. 5). 
 
Fig. 5 
HIF-1 target genes 
Once activated by hypoxia, HIF-1 binds to the consensus HIF-1 DNA binding site (HBS) ACGTG 
present in the hypoxia-response elements (HREs) of many oxygen-regulated genes. Table 1 
shows a compilation of the HIF-1 target genes identified. These genes are involved in oxygen 
homeostasis at the cellular, local and systemic levels. Erythropoietin activates erythropoiesis 
to enhance the systemic oxygen transport capacity. Because iron is a limiting factor in haem 
formation, erythropoiesis is sustained by increased expression of transferrin and transferrin 
receptor to enhance iron supply to erythroid cells. At the local level, HIF-1 activates VEGF, as 
well as one of its receptors (Flt-1), which induce angiogenesis leading to an increase in the 
vascular density and hence a decrease in the diffusion distance for oxygen. Local blood 
circulation is also controlled by modulation of the vascular tone through the production of 
NO (nitric oxide synthase), CO (haem oxygenase 1), endothelin-1, adrenomedullin or 
activation of the α1B-adrenergic receptor. At the cellular level, loss of ATP production in 
mitochondria is compensated by anaerobic glycolysis. Therefore, glucose uptake (glucose 
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transporters) and glycolysis (glycolytic enzymes) are upregulated by HIF-1. Besides hypoxia, 
both insulin and insulin-like growth factors, (IGF)-1 and 2, induce HIF-1α expression.55 In 
addition to glucose transporters and glycolytic enzymes, HIF-1 activates IGF-2 and the 
IGF-binding proteins (IGFBPs) 1, 2 and 3 but not 4, 5 and 6.56,57 Other pleiotropic growth 
factors and cytokines capable of inducing HIF-1 include epidermal growth factor, fibroblast 
growth factor-2, interleukin-1β and tumour necrosis factor-α..58,59 
 
Hypoxia-inducible HIF-1 target gene 
Oxygen transport: erythropoiesis 
 Erythropoietin 
 Transferrin (iron transport)  
 Transferrin receptor (iron uptake) 
Oxygen transport: angiogenesis and vascular tone 
 Vascular endothelial growth factor (VEGF) 
 Flt-1 (VEGF receptor 1) 
 Plasminogen activator inhibitor-1  
 Endothelin-1 
 Inducible nitric oxide synthase (NO production) 
 Haem oxygenase 1 (CO production)  
 Adrenomedullin  
 α1B-adrenergic receptor 
Anaerobic energy: glycolysis and glucose uptake 
 Phosphofructokinase L 
 Aldolase A 
 Glyceraldehyde-3-phosphate dehydrogenase  
 Phosphoglycerate kinase 1  
 Enolase 1  
 Lactate dehydrogenase A  
 Glucose transporter-1  
Negative feedback regulation of HIF-1 function 
 p35srj (CBP/p300 antagonist)  
Others 
 Insulin-like growth factor binding protein-1 
  Retrotransposon VL30  
Table 1: Identified HIF-1 target genes. 
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3. Mdm2 and p53 
 
The protein p53 plays a key role in maintaining the genomic integrity of cells. In response to 
DNA damage and other types of stress stimuli, p53 causes cell-cycle arrest60 or activates 
apoptosis.61,62 In normal cells, p53 is held in check until needed by Mdm2 (the murine 
double-minute clone 2, more appropriately termed human double-minute clone 2, or Hdm2) 
63. Harmful mutations of p53 are common mechanisms for the loss of p53 wild-type activity 
in tumor cells.64 But another important mechanism is overexpression of Mdm2, which leads 
to constitutive inhibition of p53; this is commonly seen in cancerous cells containing wild-
type (WT) p53.65,66 Because of its importance in cancer development, the p53–Mdm2 
complex is a really interesting target for anticancer drug design. It has been shown that a 
p53 homologue is sufficient to induce p53-dependent cell death in cells overexpressing 
Mdm2,67 and that a peptide as short as six residues could bind to Mdm2 in the same 
manner.68 Medicinal chemistry modifications to the same 6-residue peptide dramatically 
increased its inhibitory activity.69 Small p53 mimics would be expected to disrupt the 
p53-Mdm2 complex, consequently liberating p53 to initiate cell-cycle arrest or apoptosis. 
The MDM2 gene was originally identified on double-minute chromosomes of spontaneously 
transformed mouse 3T3 fibroblasts (mouse double minute),70 and the Mdm2 protein was 
later found to be physically associated with p53.71 
Mdm2 is a member of the really interesting new gene 1 (RING) domain family of E3 ubiquitin 
ligases. The full-length transcript of the MDM2 gene encodes a protein of 491 amino acids 
with a predicted molecular weight of 56kDa. This protein contains several conserved 
structural domains including an N-terminal p53 interaction domain (Fig. 6). The Mdm2 
protein also contains a central acidic domain (residues 230-300). The phosphorylation of 
residues within this domain appears to be important for regulation of Mdm2 function. In 
addition, this region contains nuclear export and import signals that are essential for proper 
nuclear-cytoplasmic trafficking of Mdm2. Another conserved domain within the Mdm2 
protein is a Zinc finger domain. Mdm2 also contains a C-terminal RING domain (amino acid 
residues 430-480), which contains a consensus sequence that coordinates two molecules of 
zinc. 
 
 
Fig. 6 
Like other RING domain proteins, Mdm2 functions as an adaptor protein, as an E3 ubiquitin 
ligase responsible for the ubiquitination and degradation of p53.72–74 Ubiquitination of 
proteins occurs through a complex series of steps that involve E1, E2, and E3 proteins.75,76 
The E1 enzyme binds ubiquitin, a 76-amino acid protein, activating ubiquitin for further 
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processing. The E2 conjugating enzyme accepts the activated ubiquitin from E1 and transfers 
it to the E3 enzyme, a ligase that covalently binds the ubiquitin to the substrate. Mdm2 
functions as the E3 ligase to ubiquitinate p53 at several lysine residues.77,78 It also has the 
ability to ubiquitinate itself.79,80 Mdm2 together with the p300, transcriptional co-activator 
protein, mediates the ubiquitination and proteasome-dependent degradation of the p53 
tumor suppressor protein and other growth regulatory proteins.81–83 In addition to 
mediating degradation of p53, Mdm2 blocks the interaction of p53 with the transcriptional 
apparatus 71, mediates translocation of p53 to the cytoplasm,84 thereby removing it from its 
site of action, and recruits the histone deacetylase HDAC1 to deacetylate key residues of p53 
thus making them available for ubiquitination.85 
Mdm2 and p53 are linked to each other through an autoregulatory negative feedback loop 
aimed at maintaining low cellular p53 levels in the absence of stress. In normal cells, p53 
activity is kept low by Mdm2, p53 stimulates the expression of Mdm2; Mdm2, in turn, 
inhibits p53 activity because it stimulates its degradation in the nucleus and the cytoplasm, 
blocks its transcriptional activity, and promotes its nuclear export (Fig. 7). 
 
 
Fig. 7 
In response to DNA damage, p53 is activated by disrupting Mdm2 association and stabilized 
against Mdm2-dependent degradation. p53 activation and stabilization likely are achieved 
by post-translational modifications; known modifications to p53 include phosphorylation, 
acetylation, and ubiquitination. 
Crystallographic data showed that the N-terminal domain of Mdm2 forms a deep 
hydrophobic cleft into which the transactivation domain of p53 binds (amino acids 19-26), 
thereby concealing itself from interaction with the transcriptional machinery.86 This suggest 
that amino acids 16–24 of Mdm2 can form a “flexible lid” that folds over and stabilizes the 
Mdm2 structure.87 The key to the interface is a triad of hydrophobic and aromatic amino 
15 
 
acids of p53 — Phe19, Trp23, and Leu26 — which inserts deep into the Mdm2 cleft. The 
interface relies extensively on van der Waals contacts and the steric complementarity 
between the Mdm2 cleft and the hydrophobic face of the p53 helix as these interactions are 
augmented by only two intermolecular hydrogen bonds (Fig. 8). 
 
 
Fig. 8 
The Mdm2 cleft is lined with 11 hydrophobic and aromatic amino acids that make multiple 
van der Waals contacts to p53 (Leu54, Leu57, Ile61, and Met62 from the α2 helix, Tyr67, 
Val75, Phe91, and Val93 from the middle β sheet, and Ile99, and Ile103 from the α2′ helix).  
Because the hydrophobic p53-Mdm2 interaction is structurally and biologically well 
understood, the design of small lipophilic molecules that disrupt or prevent the interaction is 
currently a therapeutic strategy. Only the Mdm2 partner has structurally well-defined 
binding sites. This implies that inhibitors should mimic p53 rather than Mdm2. Another 
reason is that only the p53 interface is composed of a single short contiguous stretch of 
amino acids. All these features favor the possibility that a small inhibitory molecule might 
work. An increasing number of small-molecule p53-Mdm2 binding inhibitors have been 
discovered and published in recent years, but only few compounds have acceptable cellular 
potency and selectivity for their molecular target and might represent viable leads for 
development of therapeutic agents.88 In order to design an effective p53 mimic as inhibitor 
of human Mdm2, it is important to understand the p53-Mdm2 interaction at the atomic 
level. Recently, in different molecular dynamics (MD) studies, the p53-Mdm2 system was 
investigated to explore the binding interface, and the effect of mutating key residues in the 
human p53-Mdm2 complex. The first calculation was a 400 ps molecular dynamics 
simulations by Massova and Kollman.89 Other studies were published from 2005 to date, and 
they were always referred to Mdm2 and the endogen ligand.90–93 Carlson et al.90 have 
applied a 2ns MD simulation to examine the binding interface in the human p53-Mdm2 
complex in order to design a potent p53 mimic. This study suggested that an additional 
hydrofobic pocket interior of Mdm2 should possibly be used to design new inhibitors. 
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Recently Verma et al.94 have applied MD simulations to investigate the binding of p53 
peptide and nutlin to Mdm2 and MdmX. Simulations reveal that p53 has a higher affinity for 
Mdm2 than MdmX, driven by stronger electrostatic interactions. The differences are more 
pronounced for nutlin because it is a small molecule whose binding is driven by short range 
van der Waals interactions and lacks the long range electrostatics that mediate interactions 
with p53, supporting findings of how the Mdm2 surface (and MdmX) modulates and is 
modulated by ligands. In work carried out on the X-ray structure of MdmX bound to a 
single-domain antibody by Fersht et al.95, the authors studied structural changes to a 
common conformation on removal of the ligand. The binding pocket converged to a 
common conformation after removal of the ligands, indicating that the differences are due 
to induced fit. However, the residues that comprise the Mdm2 lid are not conserved in 
MdmX; and also crystal structure of nutlin complexed to Mdm2 (1RV1) used for the 
simulation does not contain information concerning the lid. 
Based on available structural data and computational studies, we can classify the 
conformational states of Mdm2 into the following three broad groups: open state, closed 
state and apo state.96 These broad changes in its conformation could be an important 
starting point for designing new inhibitors. 
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4. Adenosine receptor A3 
 
The adenosine class of heterotrimeric guanine nucleotide-binding protein (G-protein) 
coupled receptors (GPCRs) mediates the important role of extracellular adenosine in many 
physiological processes. Adenosine is an ubiquitous neuromodulator that acts by stimulating 
four cell surface receptors (A1, A2A, A2B, A3), all being part of the huge family of the GPCRs. 
These receptors are widely distributed throughout the tissues. A2A and A2B receptors are 
coupled to adenylate cyclase activity, and their stimulation increases the intracellular cyclic 
adenosine monophosphate (cAMP) concentration, while A1 and A3 receptor stimulation 
decreases cAMP concentration and raises intracellular Ca2+ levels by a pathway involving 
phospholipase C (PLC) activation (Fig. 9).97,98 
 
 
Fig. 9: Adenosine class of heterotrimeric guanine nucleotide-binding protein coupled receptors. 
The A3R is involved in the control of the cell cycle and inhibition of tumour growth both in 
vitro and in vivo.99 In fact adenosine A3 receptors have been demonstrated to be more 
highly expressed in tumours than in healthy cells, suggesting a role for A3R as a tumour 
marker.33 In accordance with this notion, A3R antagonists are potential therapeutic agent 
and provide an opportunity for the generation of novel compounds that can be used as 
antitumor drugs. 
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All adenosine receptors have in common a core domain consisting of seven transmembrane 
helices (TM1 to TM7), with each TM composed of 20–27 amino acids, connected by three 
intracellular (IL1 to IL3) and three extracellular loops (EL1 to EL3). The N-terminus is located 
at the extracellular side of the cell and often contains one or more glycosylation sites. The 
C-terminus is located intracellularly and contains phosphorylation and palmitoylation sites, 
which are involved in regulation of receptor desensitization and internalization.100 All 
adenosine receptors, with the exception of the A2AR, contain a palmitoylation site near the 
C-terminus. The A2AR is the only subtype with an extraordinary long C-terminus.101 All the 
adenosine receptors are glycosylated on the second extracellular loop, although 
glycosylation does not appear to influence ligand binding. The third intracellular loop and/or 
the C-terminus are involved in coupling the adenosine receptors to G-proteins. The A1, A2B, 
and A3 receptors are very similar in regard to the number of amino acids composing their 
primary structure, the human homologs consist of 326, 328, and 318 amino acid residues, 
respectively. Conversely, the human A2A is composed by 409 amino acids. The human A1R 
and human A3R display 46.5% overall sequence identity at the amino acid level, while the 
human A2AR and human A2BR are 46.6% identical (Table 2). 
 
 A2A A2B A3 
A1 38.3 44.0 46.5 
A2A  46.6 31.0 
A2B   35.7 
Table 2: Percentage of sequence identity. 
The A3 adenosine receptor has 318 amino acids and contains 7 TM helices connected by 
three intracellular and three extracellular loops (Fig. 10-11). 
 
Fig. 10: Secondary structure of A3R. 
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Fig. 11: Schematic representation of the human A3 adenosine receptor. 
For many years, rhodopsin had represented the only structural information available for 
GPCRs. The first resolved structure of rhodopsin was published in 2000 by Palczewski et al.102 
and it had been broadly used as template.103 In 2008 the crystal structure of the human A2A 
adenosine receptor in complex with a selective antagonist ZM241385 (PDB ID: 3EML) has 
been determined (Fig. 12).104 Crystallographic model reveals features different from 
previously reported GPCR structures (Table 3). 
Protein or complex PDB code Resolution Species 
 
Rhodopsin 
1F88, 1GZM, 1HZX, 1L9H, 
1U19, 2G87, 2HPY, 2I35, 
2I36, 2I37, 2J4Y, 2PED, 
2X72, 3C9L, 3CM9, 3CAP, 
3DQB, 3OAX, 3PQR, 3PXO 
2.2-4.15 Å bovine 
β1-Adrenergic receptor 2VT4, 2Y00, 2Y01, 2Y02, 
2Y03, 2Y04 
2.5-3.05 Å turkey 
β2-Adrenergic receptor 2R4H, 2R4S, 2RH1, 3D4S, 
3KJ6, 3NY8, 3NY9, 3NYA, 
3PDS 
2.4-3.5 Å human 
Adenosine A2A receptor 3EML, 3QAK 2.6-2.7 Å human 
Table 3: Reported GPCR structures. 
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Fig. 12: Crystal structure of the human A2A adenosine receptor in complex with ZM241385. 
 
Fig. 13: Superimposition of A2A adenosine receptor (green) with bovine rhodopsin (purple) (a), β1AR (orange) (b), β2AR 
(yellow) (c). 
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The organization of the extracellular loops is markedly different from β1AR, β2AR and bovine 
rhodopsin (Fig.13).105–107 
Furthermore ZM241385 binds A2A in conformation perpendicular to the plane of the 
membrane and co-linear with transmembrane helix VII, interacting with both EL2 and EL3. 
Finally, the binding pocket of the A2A adenosine receptor results closer to helices VI and VII 
and only limited interactions with helices III and V are allowed. 
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5. Aim of the work 
 
Tumor hypoxia can be found in almost every solid tumor and it is now widely recognized as a 
cause of treatment failure for a wide variety of adult malignancies.108,109 HIF-1 inhibition may 
represent a global strategy for targeting the hypoxic tumor microenvironment and there is 
an extensive effort involved in identifying new more potent and specific HIF-1 inhibitors. 
However, HIFs-independent pathways may bypass or overcome HIFs inhibition. Therefore, 
HIF-1 inhibitors may have to be combined with other targeted agents or conventional 
therapies to integrate hypoxia-targeting methods to get more reasonable results. Focusing 
research attention on these questions would thus not only be very beneficial for 
understanding the multifaceted roles of hypoxia on the hallmarks of human cancers but also 
facilitate the rational design of combination therapies to target hypoxia for cancer 
treatment.  
Dysregulation of HIF-1 appears to play a central role for cancer therapy. Selection of the 
most appropriate point of therapeutic intervention to modulate HIF activity is also an 
important factor in pharmaceutical development. In this respect, selective inhibition of the 
HRE appears to be an attractive target. Our interest is focused on designing compounds that 
can form stable complexes with DNA and therefore we carried out docking studies on 
molecules which show a planar moiety, with the aim of performing a fast in silico screening 
of new potential DNA-interactive drugs. Another strategy to achieve inhibition of the hypoxic 
response in tumours is to target the binding interaction between the CH1 domain of p300 
and the C-TAD of the HIF-1α subunit. The interaction of HIF-1α C-TAD and CBP/p300 CH1 
domain controls expression of over seventy hypoxia-inducible genes110 and inhibition of this 
complex should therefore downregulate multiple genes in a pathway-dependent manner.  
Finally, given the important role of Mdm2 overexpression, amplification, or activation in the 
development of many tumors, the ability to inactivate Mdm2 function in such tumors would 
provide a potentially significant approach for therapy. 
Also an interesting observation is the higher level of adenosine in hypoxia-related signaling. 
Adenosine is able to increase HIF-1α protein expression in response to hypoxia in a dose- 
and time-dependent manner. 
In particular adenosine modulates a variety of cellular functions through occupancy of A3 
receptor subtype, highly expressed in tumor cells. Therefore modulating A3 receptor 
overexpression may be a good target for the discovery of new candidates as tumor cell 
marker. 
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6. Results and discussion 
 
6.1 HIF-1α: homology modeling and docking studies 
 
The amino acid sequence (Q16665) of HIF-1α protein was obtained from SwissProt Protein 
Database.111,112 The complete protein sequence (826 amino acids) of HIF-1α was screened 
against the BLAST Database in order to identify a template structure appropriate for 
modeling. The accuracy of comparative modeling is highly dependent on the sequence 
identity between the target sequence of interest and the template sequence. High accuracy 
comparative modeling can be achieved when the target and template proteins have 
sequence identity of more than 50%, while the accuracy drops when the identity of target 
and template sequences is less than 30%.113 
The HIF-1α sequence have low identity percentage for all residues but ~73% identity in PAS 
domains. Therefore, automated homology modeling is likely to result in numerous errors. 
The major source of errors is from sequence misalignment,114–116 which can be expected in 
areas of low sequence identity. Due to template dependent limitations of homology 
modeling, another computational biology approach, known as de novo protein structure 
prediction, was undertaken. Ab initio or de novo protein modeling works on the principle 
that all the information for a protein structure lies in its amino acid sequence. This method 
builds a 3D structure based on physical principles rather than on previously solved 
structures. Several online servers, grid services and offline standalone software applications 
have been developed for de novo protein modeling.  
Amongst them, I-TASSER is one of the most widely used online servers for protein structure 
and function predictions. It works by using a combination of ab initio folding and threading 
methods. 
Models are built based on multiple-threading alignments by LOMETS117 and iterative 
I-TASSER simulations. Once the models were generated, they were subjected to structural 
assessment and validation using PROCHECK, DFIRE2 and the C-Score values from the 
I-TASSER. Ramachandran plots were generated by PROCHECK.  
Additionally, the stereochemical qualities were assessed for each predicted model. As a 
result, there were 5 predicted HIF-1α models. Software I-TASSER shows a C-score as a 
parameter that indicates the quality of the resulting protein structure (Table 4).  
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Model C-Score TM-Score RMSD 
1 -0.43 0.9051 1.67 
2 -2.46 0.7347 3.29 
3 -2.54 0.7311 3.89 
4 -2.58 0.6857 4.84 
5 -2.85 0.6135 5.05 
Table 4: C-score value in each model. 
 
A scoring function (C-score), based on the relative clustering structural density and the 
consensus significance score of multiple threading templates, is introduced to estimate the 
accuracy of the I-TASSER predictions. A large-scale benchmark test demonstrates a strong 
correlation between the C-score and the TM-score. However the correlation of RMSD with 
the C-score is not as strong as that of the TM-score. 
In addition, the formation of the topography of the five models can be used as a comparison, 
where the model is the best result in the topography better than the other model, it is seen 
from the shape folding produced in each model (Fig. 14). 
 
 
Fig. 14 
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On the basis of the obtained results, Model 2 structure gave a good C-score and the 
appearance of protein folding in tertiary structure showed typical PAS domains. Once 
generated, it was subjected to structural assessment and validation. Ramachandran plot was 
generated by RAMPAGE.118 The plot showed that Model 2 contained 0.6% of residues in the 
disallowed region, 11.7% of residues in the generously allowed region and more than 87% of 
residues were in the most favoured regions (Fig. 15). 
 
 
Fig. 15: Ramachandran Plot 
 
From the calculated structure it is clear that model has standard PAS domains fold, including 
a five-stranded antiparallel β-sheet flanked by several α-helices that lie on one face of the 
protein. The representative structure of this ensemble is very similar to those of other PAS 
domains as evidenced by the low RMSD obtained by optimized superposition of secondary 
structure elements from HIF-1α PAS and other PAS domain structures (Fig. 16). 
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Fig. 16: Superposition of secondary structure elements from HIF-1α PAS and other PAS domain structures. 
Some regions of protein (PAS domain) have been modeled with high accuracy, while others 
are more difficult to model especially when the sequence identity with templates is below 
40%. 
When stable, HIF-1α translocates to the nucleus, dimerises with HIF-1β and binds to hypoxia 
response elements in the regulatory regions of target genes. Dimerisation is an absolute 
prerequisite for DNA binding and is mediated by the bHLH and PAS domains of each subunit, 
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with the basic regions contiguous with the HLH motifs of both partners contacting the DNA 
(Fig. 17).119 
In fact it has been shown that while the isolated bHLH domains of ARNT, AHR and HIF-1α can 
form heterodimeric complexes and bind E-box-like enhancer elements in vitro; the inclusion 
of the adjacent PAS domains enhances the affinity and specificity of the protein/DNA 
interaction.120,121 
 
Fig. 17: Complex between HIF-1 and its consensus DNA sequence (PDB ID: 1D7G). 
 
A model for the complex between HIF-1 and its consensus DNA sequence (PDB ID: 1D7G) 
was downloaded from Binding DataBase,122 a public available database. This model, shown 
in Fig 17, predicted a pattern of interactions between amino acids and DNA bases which 
reflects for ARNT what is experimentally observed among different X-ray structures of other 
bHLH transcription factors possessing the H (His), E (Glu), R (Arg) triad, as ARNT does.123 
This structure was used to screen possible inhibitors against HRE, through virtual screening 
of NCI (National Cancer Institute) Database. HIF-1 was removed from the complex and the 
DNA sequence was utilized for subsequent docking experiments with Glide.124 
Structure-based virtual screening is most commonly implemented as the prediction of 
binding modes and binding affinities of each compound in the dataset, by means of 
high-throughput docking to an X-ray structure or model of the target receptor.125,126 Thus, 
from the entire NCI Database compounds which were docked, the best 10 docking solutions 
were selected (Fig. 18, Table 5). Complexes were further analyzed for their interaction. 
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Fig. 18 
 
 
Ligand 
Docking 
Score 
NSC273433  -11.587 
NSC165569  -11.460 
NSC69335  -11.260 
NSC357827  -11.233 
NSC179475  -11.205 
NSC186891  -11.204 
NSC186890  -11.152 
NSC273432  -11.118 
NSC177001  -11.064 
NSC113987  -11.061  
Table 5: Docking results 
29 
 
Many ligands having a planar structure can be effective pharmacophore moieties of 
DNA-interactive drugs because they can insert between the stacked base paired 
oligonucleotides. On the other hand, major groove-interacting drugs may act by directly 
blocking or inhibiting protein-DNA recognition. These ligands are mono- or 
bis-anthracyclines and exhibit frequently hydrogen bonding capabilities between the ligand 
groups and the base atoms situated in the DNA double helix. Examination of obtained 
complex conformations reveals common characteristics need to interact with DNA double 
helix (Fig. 19): 
- presence of -OH group is especially important for binding interactions; 
- also ligand size, with bulky ligands that form a higher number of interactions. 
 
 
Fig. 19: Mono- or bis- anthracycline ligands in complex with DNA. 
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Once HIF-1 is assembled on the HRE, it must recruit transcriptional coactivators to form an 
intact initiation complex, a process mediated by distinct transactivation domains. HIF-1α 
contain two transactivation domains, an oxygen-regulated C-terminal transactivation 
domain (C-TAD, residues 786–826) and a more centrally located designated N-terminal one 
(N-TAD, residues 531–575).127,128 
Both the N-TAD and C-TAD employ recruitment of the coactivators CBP/p300, SRC-1, and 
transcription intermediary factor 2 (TIF-2),129–131 although direct interactions have only been 
demonstrated between the C-TAD and p300 or Creb-binding protein (CBP).132 CBP and p300 
are paralogous transcriptional coactivators that are essential for linking HIF and other 
transcription factors with coactivator complexes and the basal transcriptional machinery, 
and are thus indispensable for robust transcriptional activation. 
NMR structure was available for the transactivation domain of HIF-1α (PDB ID: 1L3E). The 
p300 CH1 domain is composed of four α-helices and three Zn2+-coordination sites. The three 
longer helices (designated α1, α2, and α3) pack across each other to form a roughly 
triangular structure (Fig. 20). The three Zn2+ sites lie at the vertices of this triangle. The 
arrangement of helices α1, α2, and α3 exposes large areas of the hydrophobic core. These 
hydrophobic regions form the recognition surface for the bound HIF-1α C-TAD. The HIF-1α 
C-TAD includes four structural elements: an N-terminal extended region, two helices, αA and 
αB, and an intervening loop. 
 
Fig. 20: p300 CH1 domain (a) and HIF-1α C-TAD domain (b). 
In an effort to describe the interaction site and to explain conformational flexibility, a 20 ns 
molecular dynamics simulation was performed using the program DESMOND.133 The 
structural changes and dynamic behavior were analyzed by calculating the RMSD of the 
HIF-1α and p300 backbone in function of time (ns) (Fig. 21). 
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Fig. 21 
 
The time evolution of the RMSD with respect to the NMR structure provides a measurement 
of the convergence of the dynamical properties of the protein. The trajectory of two systems 
(HIF-1α and p300) maintains quite stable throughout the 20 ns of the simulation with 
fluctuation of about 1.5 Å. 
A series of snapshots from MD simulation was used to create an ensemble of protein 
configurations (Fig. 22). 
 
Fig. 22: HIF-1α (red) and p300 (green). 
Those configurations describe the inherent flexibility of two proteins. Each of the four 
components of the HIF-1α C-TAD domain makes significant hydrophobic interactions. The 
N-terminal extended region is anchored by Leu792 and Leu795, which pack into the 
hydrophobic core of CH1 domain. The intermolecular interactions in the N-terminal region 
seem to be primarily hydrophobic. Residues 792–795 adopt an extended conformation and 
make numerous contacts with the surface of the CH1 domain. Hydrophobic contacts are 
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made by Leu792, which fits into a shallow depression at the α1/α2 interface, and by Pro793. 
Additional the side chain of Leu795 projects into a deep hydrophobic cavity (Fig. 23). 
 
Fig. 23 
 
During the 20ns simulation, an extensive hydrogen-bond network links Leu795 with His392 
and Ser395 in the CH1 domain. Additional Pro793 in the HIF-1α C-TAD domain forms 
hydrogen bond with Gln341 (Fig. 24, Table 6). When analyzing the various complexes, the 
stabilization of the complexes was through hydrophobic interactions and reinforced by H 
bonds. 
 
Time 
AMINO ACIDS INVOLVED IN  
HYDROPHOBIC INTERACTIONS 
AMINO ACIDS INVOLVED IN H-BOND 
HIF-1α p300 HIF-1α p300 
0ns L792, P793, Q794, L795 
Q341, H368, T371, 
A391, H392, S395 
L792, P793,  
L795 
Q341, H392, 
S395 
5ns 
S790, G791, L792, P793, 
Q794, L795, T796 
Q341, P367, H368, 
T371, M372, V375, 
H392, S395 
S790, P793,  
L795 
Q341, H368, 
H392 
10ns 
G791, L792, P793,  
Q794, L795, T796 
Q341, L345, T371,  
H392, S395 
P793, L795 Q341, H392 
15ns 
L792, P793, Q794,  
L795, T796 
T371, M372, V375, 
V390, A391, H392, S395 
P793, L795 Q341, S395 
20ns 
S790, L792, P793,  
Q794, L795 
T371, V375, V390,  
A391, H392, S395 
L795 A391 
Table 6: Amino acids involved in hydrophobic and H-bond interactions for N-terminal extended region of HIF-1α C-TAD. 
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Fig. 24: Some of the important hydrophobic contacts that define the topology of the interaction during the simulation. 
 
The HIF-1α key amino acid residues in the N-terminal extended region, shown in Fig. 24f, 
were used to search in ZINC database134 small molecules that might be promising as 
potential inhibitors of the HIF-1α/p300 interaction. Identified structures (~40,000) were 
docked into the protein target, CH1 p300, using GLIDE Virtual Screening Workflow124. The 
chemical structures of ten compounds with the best XP-Docking score are presented in Fig. 
25. The conformations of these hits, when bound to CH1 p300, were also analyzed to 
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determine hydrogen-bonding and hydrophobic interactions. The docking results for the best 
XP-docking score molecules are given in Table 7, whereas the binding modes (structures and 
interacting residues) are shown in Fig. 26. 
ZINC ID XP GSCORE 
AMINO ACIDS INVOLVED IN 
HYDROPHOBIC INTERACTIONS 
AMINO ACIDS 
INVOLVED IN 
H-BOND 
8442279 -6.594 I338, I399 S395, H402, I399 
8442277 -6.096 I338, L344, M372, I399, V413 Q341 
8442281 -5.879 I338, I399, M372, P412, V413 Q341 
654240 -5.838 I338, L342, I399, P412, V413 D331 
8442211 -5.791 L337, I338, I399, P412, V413 Q398 
3901268 -5.539 I338, I399, V413 H392, S395 
8442187 -5.293 I338, A394, I399, P412, V413 Q398 
18141403 -4.642 I338, L342, I399, C406, V413 H402 
8442211 -4.449 L337, I338, I399, P412, V413 - 
8442285 -4.356 L337, I338, I399, V413 Q341, S395 
Table 7: Extra Precision (XP) Glide results for the ten lead molecules 
 
Ligands are associated to the target with hydrogen bonds and hydrophobic interactions. The 
top scored compounds showed that ligands form hydrogen interactions with Ser395, 
Gln398, Gln341, and His402. Additionally each of the ten molecules makes significant 
hydrophobic interactions with the p300 CH1 domain (Ile338, Ile399) that contribute to 
specific recognition. Also hydrophobic interactions contribute to the stability of the complex. 
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Fig. 25 
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Fig. 26 
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6.2 Mdm2: molecular dynamics studies 
 
The conformational evolution of apo-Mdm2 and bound Mdm2 was investigated by 35 ns MD 
simulations. Crystal structure of the complexed Mdm2 (PDB ID: 1T4E) was used as starting 
model. 1T4E, obtained by X-Ray crystallography, contains residues from 16 to 111, and is 
crystallized with the benzodiazepine derivative [BDZ], (4-chlorophenyl)[3-(4-chlorophenyl)-7-
iodo-2,5-dioxo-1,2,3,5-tetrahydro-4H-1,4-benzodiazepin-4-yl]acetic acid (Fig. 27). The protein 
comprises a minimal N-terminal p53 binding domain (16-25), referred to as the lid. While 
structures of Mdm2 bound to various inhibitors have been solved by X-Ray crystallography 
and NMR,135 no information is available concerning the lid behavior in apo-Mdm2. The 
limited amount of experimental data thereby precluded the accurate modeling of the lid and 
its precise binding mode to the cleft. In addition, it has been proposed that the binding event 
induces global conformational changes of Mdm2. 
 
Fig. 27: Structure of Mdm2 inhibitors. 
Here, we report the characterization of the behavior of human Mdm2 and of the lid in the 
apo state, and in complex with the inhibitors reported in Fig. 27. To study the apo state the 
ligand was removed from the protein and a 35 ns MD simulation of the free receptor was 
first carried out to extensively sample the protein conformations. Moreover a 35 ns MD 
simulation was carried out on the 1T4E. 
Further by using the obtained apo state at 0 ns, a different inhibitor IMZ, cis-[4,5-bis-
(4-bromophenyl)-2-(2-ethoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-4-(2-hydroxyethyl)
piperazin-1-yl]methanone, was docked (Fig. 27). Multiple poses of the complex were 
generated with Induced Fit Docking (IFD) by Schrödinger.136 Each complex was then ranked 
according to the IFD score which considers both the docking energy and solvation energy 
(IFDScore = GlideScore + 5% PrimeEnergy). The docking results are summarized in Table 8. 
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IMZ 
poses 
docking 
score 
Glide 
energy 
Prime 
Energy 
IFDScore RMSD 
1 -9.27 -46.87 -4613.58 -239.95 0.81093 
2 -7.36 -43.55 -4612.39 -237.98 0.81018 
3 -6.49  -47.74  -4613.70  -237.17  0.80996  
4 -1.10 -42.54 -4618.49 -232.03 0.81063 
5 0.50 -45.13 -4617.13 -230.35 0.81249 
Table 8: Induced Fit Docking results. 
Visual inspection of the top-ranked poses showed that the IFD-generated model 3 can 
reproduce a conformation that is almost identical to the native pose of the crystal structure 
of the Mdm2 bound to IMZ as found in 1RV1 in which however the lid, residues 16-25, were 
not solved (Fig. 28). So the IFD protocol led to a receptor structure able to bind IMZ that can 
be used in 35 ns MD simulation. 
 
Fig. 28: Superimposition of Mdm2 bound to IMZ (green) and IFD model (purple) 
 
We started our analysis by monitoring the structural changes occurring throughout the 
simulation of Mdm2. The structural changes resulting from the 35 ns simulation can be 
evaluated in terms of RMS Deviation. So the RMSD of the Cα atoms of the bound (1T4E+BDZ, 
1T4E+IMZ) and unbound (1T4E) systems was computed and plotted (Fig. 29). 
The trajectory of unbound system maintains quite stable up to about 10 ns and then 
increases by about 2 Å. After 20 ns increases again, then it remains stable throughout the 15 
ns of the simulation, with fluctuation of about 0.5 Å. When the RMSD of the apo form is 
compared to that of the Mdm2 bound to IMZ, it was observed that during the first 3.3 ns 
RMSD was similar and comparable. After 3.3 ns it showed a significant increase, so this trend 
clearly showed major structural deviations in the 3.3–11.3 ns range. During the rest of the 
simulation dynamics of Mdm2 bound to IMZ remains very stable and was very similar to 
apo-Mdm2. The RMSD of the Mdm2 bound to BDZ appears different from the previous one, 
and showed a significant increase during the first 6 ns of simulation. After that point the 
dynamics of the protein remained relatively stable, with fluctuation of ≈ 0.5-0.6 Å. In this 
range, RMSD was comparable with that observed in the Mdm2 bound to IMZ. During the 
rest of the simulation it showed a substantial increase on the calculated RMSD, therefore 
major conformational changes on the protein take place. Analysis of evolution in dynamics 
39 
 
of RMSD for Cα atoms showed that the structures have important variation, but the 
Mdm2-BDZ is stabilized in the last 15 ns of simulation. In contrast to Mdm2-BDZ, a small 
fluctuation of RMSD values is observed for other two simulations. Similar behavior of 
apo-Mdm2 was found in simulations carried out by Carlson137 and Pellicciari138. The 
trajectory of the p53-Mdm2 complex was very similar to that observed for Mdm2 bound to 
IMZ. p53-Mdm2 complexes were highly flexible in simulation, and IMZ and BDZ complexes 
appear to follow this trend. 
 
 
Fig. 29: RMSD of 1T4E apo and bound forms (BDZ and IMZ) 
 
The RMSD of backbone atoms in the binding pocket (Leu54, Leu57, Ile61, Met62, Tyr67, 
Val75, Phe86, Phe91, Val93, Ile99, and Ile103) is presented in Fig. 30. In apo-Mdm2, the 
binding pocket was stable throughout the trajectory with fluctuation <0.5. Binding pocket 
dynamics of Mdm2 bound to IMZ was very similar to apo-Mdm2. Instead in presence of BDZ, 
the RMSD gradually increases. When the RMSD of the lid is compared for apo and bound 
Mdm2 (Fig. 31), it was observed that IMZ induced conformational changes in the lid. The 
trajectory of lid in the apo Mdm2 is quite stable over the timescale of simulation. As seen in 
the figure, the RMSD of Mdm2-IMZ lid was ≈ 2 Å during the first 5 ns, but a rise in RMSD of 
about 2 Å was observed in subsequent ns. A rise in RMSD was observed for Mdm2-BDZ lid 
between 1 and 24 ns. During the rest of the simulation RMSD showed a significant decrease: 
this suggest the probable interaction between BDZ and the lid that helps to stabilize lid 
conformation. 
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Fig. 30: RMSD of binding pocket for 1T4E apo and bound forms. 
 
Fig. 31: RMSD of lid for 1T4E apo and bound forms. 
The simulation findings indicate the structural stability of apo protein, while the RMSDs of 
bound systems showed structural mobility. The inhibitors in the binding pocket caused the 
displacement of the lid located above the binding cleft. Also the movement of binding cleft is 
adaptive, the inhibitors allow the binding cleft to be more flexible and to better adapt itself. 
We used PCA as a guide to identify significant dynamic processes from this very large data 
set. The first step in PCA is the construction of the covariance matrix, which captures the 
degree of collinearity of atomic motions for each pair of atoms. The covariance matrix is 
subsequently diagonalized, yielding a matrix of eigenvectors and a diagonal matrix of 
eigenvalues. Each of the eigenvectors describes a collective motion of particles, where the 
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values of the vector indicate how much the corresponding atom participates in the motion. 
The sum of the eigenvalues is a measure of the total motility in the system. Compared to 
bound proteins (7.07 nm2 for 1T4E-BDZ, 4.25 nm2 for 1T4E-IMZ) the total sum of eigenvalues 
of apo system was relatively small (3.53 nm2), indicating a more rigid structure. 
 
Fig. 32: Principal components analysis computed for Mdm2 in various states: apo (green), complex with IMZ (red) and 
complex with BDZ (blue). 
 
PCA technique decomposes the intrinsic flexibility of a protein into motions of different 
frequencies of vibrations. These are then ordered such that the first component (PC1) 
characterizes the motion with the largest amplitude and lowest frequency. Principal 
components were computed for Mdm2 in various states: apo, complex with IMZ and 
complex with BDZ (Fig. 32).  
 
Fig. 33: Contributions of first ten principal components. 
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PC1 dominates the motions of Mdm2 bound to BDZ (covering 56% of overall motion). The 
motion is more distributed across PC1 and PC2 in Mdm2 bound to IMZ (21.5% PC1, 12.2% 
PC2) and apo-Mdm2 (11.7% PC1, 6% PC2). Histogram in Fig. 33 refers to the contributions of 
first ten individual principal component to the overall fluctuations. 
The distribution of the structures in the phase space defined by principal components 1 
(PC1) and 2 (PC2) shows that the BDZ and IMZ bound states are more flexible than apo one. 
The evolution of the secondary structure of the three systems was also analyzed in order to 
determine if the dynamics of Mdm2 involves changes in the secondary structure pattern. In 
order to quantitatively measure the mean backbone mobility for each residue, the root 
mean square fluctuations (RMSF) relative the average structure of apo-Mdm2 were 
calculated (Fig. 34). It was observed that the mobility of the unbound system was relatively 
low for the regions including residues 26–76, excluding the N-terminus. In this region the 
RMSF was < 1 Å. 
 
 
Fig. 34: RMSF of 1T4E apo and bound forms (BDZ and IMZ). 
Few residues (42-44 and 69-71) displayed a mobility higher than 1 Å. Specifically, residues 
69-71 form a hinge that connects helix α2 with the region formed by sheets β1’. There were 
a few residues that showed larger degree of ﬂexibility throughout the 35 ns simulation 
(RMSF > 1.3 Å) in the region including amino acids 78-81. When comparing the mobility of 
apo-Mdm2 to that observed for Mdm2 bound to IMZ, a very similar trend of RMSF was 
observed. The mobility of Mdm2 bound to IMZ is lower than apo-Mdm2, except for residues 
between 61-74, in proximity of the amino acids which constitute the hydrophobic binding 
cleft (Met62, Tyr67, Val75). Excluding the N and C-terminus, few residues displayed a 
mobility higher than 1 Å. The residues that showed the highest ﬂexibility were Lys70, Ser78, 
and Asn79 (RMSF ≈ 1.5 Å), located around the binding cleft. Residues which constitute 
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binding cleft showed larger degree of ﬂexibility. The highest RMSFs highlight the ability to 
better adapt itself to ligand (BDZ, IMZ). 
To qualitatively analyze the conformational changes experienced by the protein, the 
superimposition of three clusters of structures was analyzed (Fig. 35-37). 
 
 
Fig. 35: Superimpositions of 1T4E clusters apo forms. The backbone of apo-Mdm2 at 0 ns (blue), 10 ns (red), 20 ns 
(yellow) and 35 ns (green) are showed in square. 
 
 
Fig. 36: Superimpositions of 1T4E clusters bound to IMZ. The backbone of Mdm2-IMZ at 0 ns (blue), 10 ns (red), 20 ns 
(green) and 35 ns (turquoise) are showed in square. 
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Fig. 37: Superimpositions of 1T4E clusters bound to BDZ. The backbone of apo-Mdm2 at 0 ns (blue), 10 ns (red), 20 ns 
(green) and 35 ns (turquoise) are showed in square. 
 
Considering apo-Mdm2 superimpositions, we observed that the lid of the cleft was located 
just above the binding cleft in the first 13 ns. So residues 19–24 form a flexible lid burying a 
hydrophobic active site. Between 13 and 19 ns the lid displayed a movement outwards the 
cleft, opening the binding site. In Mdm2-IMZ system we observed that the lid of the cleft 
displayed a high degree of ﬂexibility and a wide movement outwards the cleft. The helix α2 
experienced an inward movement toward the center of the cleft. Furthermore, sheets 
β1’-β2’ showed a movement toward the center of the binding cleft leading to a more closed 
conformation of the binding pocket. Similarly, in the case of Mdm2-BDZ superimposition, the 
helix α2’ experienced an inward movement toward the center of mass of the cleft and the 
hinge that connected helix α2’ with sheets β2’, the floor of the cleft, showed a wide 
movement towards the center of the binding cleft. This inward movement was facilitated by 
the twisting motion of the hinge formed by sheets β1’ and β2’. The movement of helices and 
hinges, which constitute the cleft, contributes to the global rearrangement of the cleft, as 
observed in our simulations. The shape of the binding cleft changes and the cleft’s 
movement is influenced by the movement of hinges and helices located around. Also the 
binding site shape and size are defined by the ligand. 
The superimposition of the backbones of apo-Mdm2 and bound Mdm2 was complemented 
with the quantitative measurement of the changes in the accessible area (Fig. 38). 
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Fig. 38: SASA of 1T4E apo and bound forms (BDZ and IMZ). 
Thus, the solvent-accessible surface area (SASA) was calculated for all atoms in Mdm2, using 
a probe radius of 1.4 Å. In the apo-Mdm2 simulations the value of SASA decreased in the 
first 13 ns to a minimum value of ≈ 2930 Å2 and then increased between 13 and 19 ns, 
indicating that the structure assumes a less closed conformation as confirmed by RMSF. 
Between 19 and 23 ns the value of SASA decreased again, whereas in following ns the SASA 
value fluctuates around the average value of 2970 Å2. It was observed that, in our 
Mdm2-IMZ simulations, the value of SASA decreased in the first 4 ns to a minimum value of 
≈ 2946 Å2 and then increased during the successive ns of simulation. Between 5 and 10 ns, 
the SASA value fluctuates around the average value of 3004 Å2. After 15 ns the value of SASA 
decreased to a minimum value ≈ 2930 Å2, then dramatically increased (≈ 3072 Å2), indicating 
that the structure assumes a less closed conformation. For Mdm2-BDZ system, the value of 
SASA decreases until a minimum value of ≈ 2977 Å2 in the first ns of simulation. In following 
ns the SASA value fluctuates around the average value of 3005 Å2. After 22.5 ns the SASA 
value drastically decreases by about ≈ 100 Å2 indicating that again the structure assumes a 
less closed conformation. After that point, it remained fairly stable during the rest of 
simulation, around the value of 2993 Å2. A decrease of the SASA on the apo Mdm2 structure 
was observed, supporting the fact that the simulation converged to a closer structure 
compared to that obtained for bound systems. In fact the presence of the ligands influenced 
the cleft shape that assumes a less closed conformation. For the apo system the lid situated 
above the binding cleft displayed a lower degree of ﬂexibility forming a less exposed cavity. 
Another interesting feature observed in our simulations was the dynamics of the side chains 
of key residues at the binding pocket (χ angle), Leu54, Leu57, Ile61, Met62, Tyr67, Val75, 
Phe86, Phe91, Val93, Ile99, and Ile103. Leu57 of Mdm2 interacts with p53 via the formation 
of a hydrogen bond between the Trp23 ε-nitrogen of p53. 
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Fig. 39: Side-chain motions of 1T4E apo forms at 10 ns (yellow), 20 ns (orange), 30 ns (purple). 
 
When Mdm2 is unbound (Fig. 39), Leu57 displayed rapid transitions going from -170° to 
+170°. No signiﬁcant differences were observed in the type of motions displayed by Met62, 
Tyr67, Val75, Phe86, and Leu54. Also for Phe91 and Val93 no substantial differences in the 
type of motions were observed for the first 23 ns. After that point they displayed rapid 
transitions. 
 
 
Fig. 40: Side-chain motions of 1T4E bound to BDZ at 10 ns (yellow), 20 ns (green), 30 ns (red). 
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Fig. 41: Side-chain motions of 1T4E bound to IMZ at 10 ns (yellow), 20 ns (orange), 30 ns (green). 
In the case of Mdmd2 bound to BDZ (Fig. 40), few differences were observed in the type of 
motions displayed by Leu54, except rapid transitions going from -60˚ to +164˚ and from 
-145˚ to +178˚ after 16 and 26 ns respectively. A similar situation was noticed for Leu57, 
which displayed transition movements in the range from -160˚ to +170˚, and for Met62. Also 
few differences were observed in the type of motions displayed by Tyr67 and Phe86. Val75 
displayed rapid transitions going from -170˚ to +177˚ and a similar situation was noticed for 
Phe91 and Val93. Comparing the Mdm2-IMZ librational motions to the Mdm2-BDZ 
librational motions (Fig. 41), a slight different behaviour was observed. A similar situation 
was noticed for Leu54, Leu57, Val75 and Val93, which displayed transition movements in the 
range from -180˚ to +170˚. Similarly few differences were observed in the type of motions 
displayed by Tyr67, Phe86 and Phe91. The binding of two different ligands (IMZ and BDZ) to 
the cleft requires specific side-chain movements and local arrangements of the cleft. 
Side-chain fluctuations of the amino acids located at the binding cleft allow the binding cleft 
to be more flexible and to adapt itself to incoming ligand. The compounds studied herein 
tried to mimic the domain of p53 that binds to Mdm2. 
To investigate the binding mode of these compounds, we analyzed the structure of the last 
snapshot of Mdm2 bound to the two different inhibitors (IMZ and BDZ) obtained after 35 ns 
simulations. 
When the Mdm2–IMZ at 0 ns was analyzed, the structure verified that the inhibitor binds to 
the p53 binding site on Mdm2. The inhibitor mimics the interactions of the p53 peptide to a 
high degree, with one bromophenyl moiety sitting in the Trp pocket, the other bromophenyl 
group occupying the Leu pocket, and the ethyl ether side chain directed toward the Phe 
pocket.139 In essence, the imidazoline scaffold replaces the helical backbone of the peptide 
and is able to direct, in a fairly rigid fashion, the projection of three groups into the pockets 
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normally occupied by Phe19, Trp23, and Leu26 of p53.86 As shown in Fig. 42, the bound 
conformation of IMZ was similar to the p53 peptide; for the p53-bound Mdm2, we used the 
X-ray structure 1YCR. 
 
Fig. 42: IMZ superimposed to bound p53 (PDB ID: 1YCR). 
IMZ interacts with Gln72 through the hydroxyethyl group of the IMZ, which donates a 
hydrogen bond to the side-chain oxygen of Gln72. We observed that one bromophenyl 
group established non polar interaction with Leu54, the other bromophenyl group with 
Leu57, Phe86, Phe91, Ile99 and Ile103. In addition the ethyl ether side chain of the IMZ 
established non polar interaction with Tyr67 and Ile61. When the protein-ihibitor complex, 
as obtained after the simulation, was analyzed, we found that bromophenyl groups 
established non polar interaction with Leu57, Gly58, Ile61, Val93 and His96. The 
hydroxyethyl group of the IMZ formed non polar interaction with Gln72, the piperazine 
group with Tyr67, and 2-ethoxy- 4-methoxyphenyl group with His73 and Ala43.  
In the other investigated complex, 1T4E-BDZ, the inhibitor occupies the same pockets of the 
peptide p53 side chains Phe19, Trp23, and Leu26 (Fig. 43). 
 
 
Fig. 43: BDZ superimposed to bound p53 (PDB ID: 1YCR). 
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As in the case of bound peptides, the Mdm2 interactions with the inhibitor were largely 
nonspecific van der Waals contacts. The BDZ pendant groups orient themselves to mimic the 
position of the hydrophobic side chains on one face of the helical p53 peptide ligand and 
thus act as an α-helix mimetic, with one chlorophenyl moiety sitting in the Leu pocket, the 
other occupying the Trp pocket, and the dioxo-tetrahydro-benzodiazepine moiety in the Phe 
pocket. When the protein-inhibitor complex, as obtained after 35 ns MD, was analyzed, we 
found that chlorophenyl groups established non polar interaction with Val93, Lys94, His96, 
Tyr100 and Ile103, the core benzodiazepine ring formed non polar interaction with Ile61, 
Tyr67, Lys94 and Gln72.  
These findings are in partial agreement with the data reported in the paper by Pellicciari et 
al.138 in which the authors performed a linear discriminant analysis (LDA) with the aim of 
identifying specific residues whose conformational changes are the marker of the apo and 
p53-bound states of Mdm2 and MdmX.138 In IMZ-Mdm2 it was possible to identify two 
residues that are involved in the shape arrangement of the p53 binding site: Gln72 and 
His73. Gln72 and Tyr100 are identified in BDZ-Mdm2. Other residues, identified as involved 
in the shape arrangement of the binding site, were Ala43, Leu57, Gly58, Ile61, Tyr67, His73, 
Val93, Lys94, His96, and Ile103. 
Therefore ligands make extensive van der Waals contacts with residues in the peptide 
binding cleft comprised of the structural elements α2, β1’, and α2’. These residues are: 
Leu54, Leu57, Ile61 and Met62 in helix α2; Tyr67, Phe91, and Val93 in β1’ sheet; and His96 
and Tyr100 in helix α2’. These interactions support the observed changes in the backbone 
residues known to be in direct contact with the ligands. Both ligands caused similar changes 
in the peptide binding cleft. It was observed that, in our Mdm2-IMZ simulation, Leu57, Ile61 
and Met62 (in helix α2) showed an inward movement toward the center of the binding cleft. 
On the contrary Phe91 showed an outward movement of about 1.5 Å. The larger difference 
was in Phe86, that showed an inward movement of about 3 Å. In Mdm2-BDZ simulation 
Ile61, Met62, Tyr67 and Phe91 showed an inward movement toward the center of the 
binding cleft. The larger differences were in His96 and Val93, that showed an inward 
movement of about 2 Å. The main conformational changes were found in linker turn regions 
or in the β sheets. These conformational changes seem to be sufficient to accommodate 
ligands that differ in their length: the changes alter the size of the cleft and indirectly affect 
the angle of the bottom α helices with respect to the cleft. The analysis of the results 
obtained by molecular dynamics of apo system showed a stable and less flexible structure, 
with the lid closing the binding cleft of the protein and leading to a closed conformation of 
the cleft (Fig. 44). 
These findings are confirmed by SASA mean values that highlight the importance of the 
ligand affecting the binding cleft by assuming a different conformation in Mdm2 with 
respect to the apo form. Mdm2 shows an high solvent exposition in the bound form with 
respect to the apo form, with this behavior being ascribed to changes in the size of the cleft 
and to a high degree of ﬂexibility of the lid in bound systems. 
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Fig. 44: apo-Mdm2 snapshots; binding pocket highlighted in the box. 
On the contrary in the bound systems the lid displayed a high degree of ﬂexibility and a wide 
movement outwards the cleft, forming a wider and more exposed cavity (Fig. 45-46). 
 
Fig. 45: Mdm2-IMZ snapshots; binding pocket highlighted in the box. 
 
Figura 46: Mdm2-BDZ snapshots; binding pocket highlighted in the box. 
In summary, in this study, the influence on Mdm2 structure upon binding of different ligands 
was analyzed. A rearrangement and an outward expansion of the Mdm2 helices, 
surrounding the binding cleft in bound systems, was observed. Ligand IMZ caused the most 
prominent changes in the β-sheets surrounding the binding cleft (β2′), whereas BDZ 
produced its most significant changes in the antiparallel β-sheets, the linker regions between 
the β-sheets and the α-helices that form the bottom and side walls of the cleft. It seems that 
the Mdm2 domain has an intrinsic flexibility that enables it to adapt its conformation to 
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ligands. The conformational changes alter the size of the cleft and were mainly in the linker 
regions suggesting that the overall dynamic nature of Mdm2 is related to dynamic 
movements in these regions. NMR spectroscopy studies96 confirm the observation that 
changes in chemical shift were mainly in the linker regions between the secondary structure 
elements and suggests that the overall dynamic nature of Mdm2 is related to dynamic 
movements in these regions, which can occur without any loss of the secondary structure 
scaffold. Also the MD studies based on 1T4E X-ray structure showed that in the apo-state the 
lid exists in a dominant closed form, whereas in bound system exists in a open form in which 
the lid extends away from the binding cleft, allowing a full access of ligands to the binding 
pocket. This study concluded that the binding cleft is very adaptable and that different 
ligands might induce global conformational changes. The opening up of a ligand-binding 
pocket suggests that compounds inserted at this position might raise further conformational 
change and hence increase the pocket plasticity. 
 
6.3 A3 receptor: homology modeling and 3D-QSAR studies 
The A3 protein sequence was collected from the Swiss-Prot Protein Database (P33765).140,141 
The A2A adenosine receptor can be considered the best template for homology modeling 
according to the percentage identity of the aligned sequence. Identity increases from a 
comparison of bovine rhodopsin to hA2A adenosine receptor. The increase is even higher 
when comparing only TM regions and if N- and C-terminus are not taken into consideration 
(Table 9). 
    Rhodopsin hA2A 
All 
hA1 15.3 38.3 
hA2A 14.5 100 
hA2B 19.5 46.6 
hA3 14.4 31 
TM regions 
hA1 15.7 60.8 
hA2A 23.2 100 
hA2B 22 68.6 
hA3 19.3 50.3 
All except 
N and C-terminus  
hA1 16.4 51.7 
hA2A 21.2 100 
hA2B 22.9 61.6 
hA3 16 41.9 
Table 9: Percentage identity of aligned sequences. 
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Two different models of hA3R were generated by LOMETS117 using the bovine rhodopsin 
(PDB ID: 1U19) and the hA2A adenosine receptor (PDB ID: 3EML) as templates (Fig. 47). 
 
Fig. 47: Superposition of hA3 models built using rhodopsin (green) and hA2A (purple) as templates. 
As it is seen from the RMSD of the aligned models, the main differences among the two 
models are found within EL2 and IL3 loops (Table 10). In particular EL2 belongs to the 
binding pocket and interacts with ligand. In the model built using hA2A as template, the 
binding pocket is open to extracellular side and closer to TM6 and TM7. 
 RMSD 
Backbone 7.08 
IL1 1.18 
IL2 3.01 
IL3 6.26 
EL1 3.47 
EL2 6.74 
EL3 1.36 
TM1 0.70 
TM2 1.37 
TM3 0.98 
TM4 1.39 
TM5 1.03 
TM6 0.75 
TM7 0.93 
Table 10: RMSD of the aligned hA3 adenosine receptor models built using A2A and rhodopsin. 
Then new structure of hA2A adenosine receptor improved modelization of A3 adenosine 
receptor. Obtained model was refined using MoodLoop,142 and was ranked on QMEAN 
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server.143 The model created using template 3EML had Qmean score = 0.47, indicating good 
quality of model produced, while the one generated using template 1U19 had Qmean score 
= 0.40. The overall stereochemical quality of the model was assessed by PROCHECK144 and 
the validation of the structure was performed by inspecting the psi/phi Ramachandran plot 
(Fig. 48). 
 
Plot Statistics 
Residues in most favoured regions [A,B,L] 279 94.3% 
Residue in additional allowed regions [a,b,l,p] 16 5.4% 
Residue in generously allowed regions [~a,~b,~l,~p] 1 0.3% 
Residue in disallowed regions 0 0.0% 
Number of non-glycine and non-proline residues 296 100.0% 
Number of end-residues (excl. Gly and Pro) 2  
Number of glycine residues (shown as triangles) 11  
Number of Proline residues 9  
Total number of residues 318  
Fig. 48: Ramachandran plot of obtained model. 
 
The Ramachandran plot showed 94.3% of the residues in the most favorable region, 5.4% in 
the allowed region, 0.3% in the generously allowed region. This result revealed that the 
obtained model is reliable and of good quality. 
Homology models represent a rigid conformation of a protein, but proteins are dynamic and 
show rapid, small-scale structural fluctuation.145 Obtained model supposed to be antagonist-
like state of A3 receptor and it can exist in more than one conformational state. Therefore a 
20 ns molecular dynamics simulation in a lipid bilayer was performed to explain 
conformational flexibility and structural stability, using the program DESMOND.133 
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The structural changes and dynamic behavior were analyzed by calculating the RMSD of the 
TMs (Fig. 49) and loops (Fig. 50) backbone in function of time (ns). 
 
 
Fig. 49: RMSD of the TMs backbone in function of time. 
 
 
Fig. 50: RMSD of the loops backbone in function of time. 
 
Very short loop, such as IL1, EL1, and EL3, have low values of RMSD, together with bigger 
loop like IL2. N-term and C-term are very flexible, probably due to the fact that are more 
exposed. Bigger loop like IL3 and EL2 are more flexible (Fig. 51). TMs show that the 
conformation is more stable through 20 ns of simulation. The RMSD values of the backbone 
atoms in the system tend to converge after 7 ns, showing fluctuations of around 1 Ǻ. The low 
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RMSD value during the simulation time indicated that the 3D structural model represents a 
stable folding conformation. 
 
 
Fig. 51: EL2 of the hA3 adenosine receptor before (purple) and after (green) 20ns of molecular dynamics. 
A number of activity data for A3 adenosine receptor inhibitors, that belong to diverse 
chemical classes, are currently avalaible. Biological activity data of 121 hA3R antagonists, 
represented as pKi, were collected from different literature papers.146–152 All antagonist 
structures were docked into TM binding site of the hA3 model using GLIDE124 (Fig. 52). 
 
Fig. 52: Antagonists structures docked into TM binding site of hA3. 
The resulting docked complexes were imported in PHASE module153 for the development of 
3D Quantitative Structure–Activity Relationship (QSAR) Pharmacophore model. All reported 
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A3 receptor antagonists have been clustered into four groups: triazolo-quinoxaline, (Group 
1) (Fig. 53a); pyrazolo-quinoline, (Group 2) (Fig. 53b,c); annelated triazolo-pyrazine, (Group 
3) (Fig. 53d-g); other heterocyclic derivatives, (Group 4) (Fig. 53h-n). The prepared ligands 
were then used to generate common feature pharmacophore models, which, in turn, were 
utilized to generate 3D-QSAR models. 
 
Fig. 53: A3 adenosine receptor inhibitors: triazolo-quinoxaline derivatives (a), pyrazolo-quinoline derivatives (b-c), 
annelated triazolo-pyrazine derivatives (d-g), heterocyclic derivatives (h-n). 
The datasets of compounds were divided into training and test sets. Two different 
approaches for splitting the datasets were used. In the first one, training sets were 
constructed by choosing a percentage (80%) of the total number of compounds in each bin 
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randomly. The other approach is based on Kohonen map-artificial neural network, now more 
widely called self organizing maps (SOM).154,155 Descriptors calculation, and autoscaling of 
descriptors matrix were the starting point to perform Kohonen clustering approach. The 
selected test set members are characterized by the minimal distance from the centroid of 
each cell in the top map. Common pharmacophore features were identified and scored. The 
generated pharmacophore hypotheses for these groups consisted of four features: one 
acceptor site (A), and three aromatic ring sites (R). The alignments of all the ligands to the 
top-ranked pharmacophores were used to generate QSAR models, setting the number of 
partial least square (PLS) factors from 1 to 6 (Fig. 54). 
 
Fig. 54: Pharmacophore mapping of the most active compounds (left); superimposition of active compounds with the 
pharmacophore. 
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Predicted activity of test set compounds was plotted against their experimental activity, and 
the relevant statistics were computed. Phase statistical analysis for the four groups, labelled 
as Groups 1-4, for each of test set selection method is shown in Tables 11 and 12. 
 
Group 1 
Factors SD R
2
 RMSE R
2
pred R-Pearson RMSE/SD Δ 
Opt. 
Model 
1 0.62 0.66 0.52 0.19 0.61 0.84  - 
2 0.46 0.82 0.65 0.64 0.85 1.15 0.30 - 
3 0.31 0.92 0.38 0.57 0.76 1.21 0.06 √ 
4 0.20 0.97 0.44 0.42 0.70 2.17 0.96 - 
5 0.13 0.99 0.38 0.57 0.79 2.97 0.80 - 
6 0.08 0.99 0.38 0.57 0.78 4.52 1.55 - 
 
Group 2 
Factors SD R
2
 RMSE R
2
pred R-Pearson RMSE/SD Δ 
Opt. 
Model 
1 0.56 0.41 0.32 0.69 0.91 0.57  - 
2 0.33 0.80 0.34 0.65 0.85 1.01 0.44 - 
3 0.26 0.88 0.32 0.69 0.89 1.22 0.21 - 
4 0.21 0.93 0.33 0.67 0.88 1.58 0.36 √ 
5 0.15 0.96 0.29 0.75 0.95 1.87 0.29 - 
 
Group 3 
Factors SD R
2
 RMSE R
2
pred R-Pearson RMSE/SD Δ 
Opt. 
Model 
1 0.61 0.48 0.74 0.10 0.64 1.21  - 
2 0.46 0.72 0.58 0.45 0.83 1.26 0.04 - 
3 0.35 0.84 0.46 0.65 0.88 1.31 0.05 - 
4 0.29 0.90 0.45 0.67 0.91 1.56 0.25 √ 
 
Group 4 
Factors SD R
2
 RMSE R
2
pred R-Pearson RMSE/SD Δ 
Opt. 
Model 
1 0.44 0.69 1.03 0.31 0.96 2.34  - 
2 0.26 0.90 0.00 0.34 0.96 0.01 -2.33 √ 
3 0.16 0.96 0.98 0.37 0.97 6.01 6.00 - 
Table 11: 3D-QSAR Results Summary for random selection of test set (Factors =number of factors in the partial 
least squares regression model; SD = standard deviation; RMSE = root-mean-square error; R
2
pred = value of the 
predicted activities for test set; R-Pearson = Pearson R value for the correlation between the predicted and 
observed activity for the test set; Δ = difference from preceding). 
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Group 1 
Factors SD R
2
 RMSE R
2
pred R-Pearson RMSE/SD Δ 
Opt. 
Model 
1 0.55 0.71 0.99 -0.85 -0.08 1.80 - - 
2 0.38 0.86 1.08 -1.24 -0.20 2.83 1.02 - 
3 0.25 0.94 1.02 -1.00 -0.18 4.10 1.27 √ 
4 0.13 0.99 1.12 -1.37 -0.23 8.70 4.60 - 
5 0.08 0.99 1.09 -1.28 -0.19 14.24 5.54 - 
6 0.06 1.00 1.09 -1.27 -0.20 18.36 4.12 - 
 
Group 2 
Factors SD R
2
 RMSE R
2
pred R-Pearson RMSE/SD Δ 
Opt. 
Model 
1 0.56 0.42 0.47 0.33 0.60 0.83 - - 
2 0.38 0.75 0.44 0.40 0.70 1.16 0.33 - 
3 0.28 0.87 0.28 0.75 0.89 1.02 -0.14 - 
4 0.23 0.91 0.27 0.77 0.89 1.17 0.15 √ 
5 0.18 0.95 0.25 0.81 0.90 1.39 0.22 - 
 
Group 3 
Factors SD R
2
 RMSE R
2
pred R-Pearson RMSE/SD Δ 
Opt. 
Model 
1 0.63 0.46 0.94 -0.19 -0.26 1.48 - - 
2 0.40 0.80 0.83 -0.18 -0.07 2.10 0.62 - 
3 0.29 0.90 0.75 0.03 0.25 2.57 0.47 - 
4 0.19 0.96 0.84 -0.20 0.08 4.51 1.94 √ 
 
Group 4 
Factors SD R
2
 RMSE R
2
pred R-Pearson RMSE/SD Δ 
Opt. 
Model 
1 0.40 0.82 0.62 0.09 0.59 1.55 - - 
2 0.21 0.95 0.69 -0.12 0.54 3.27 1.72 √ 
Table 12: 3D-QSAR Results Summary for SOM selection of test set (Factors =number of factors in the partial least squares 
regression model; SD = standard deviation; RMSE = root-mean-square error; R
2
pred = value of the predicted activities for 
test set; R-Pearson = Pearson R value for the correlation between the predicted and observed activity for the test set; Δ = 
difference from preceding). 
 
A statistical analysis which included the R2 versus RMSE/SD plot was employed to choose the 
best PLS model for the different set selection methods. The best model was chosen on the 
basis of PLS factor model minimum observed in RMSE/SD value, with R2 value still higher 
than 0.9. Only models with good statistical parameters for the training set and exhibiting 
good predictive ability against a test set were chosen. Group 4 did not exhibit excellent 
statistical prediction in both of test set selection method was not taken into account. 
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Group 2 exhibited comparatively better PLS statistical qualities and excellent prediction of 
the external test set compounds in both of test set selection method; it showed correlation 
coefficient (R2) of 0.96 for random selection of test set, test set prediction (R2pred) of 0.75 and 
R-Pearson of 0.95. The low standard deviation (SD) and root-mean-squared error (RMSE) 
contributes significantly to the model. 
For Groups 1-3, the most significant models were obtained with Random selection approach, 
because R2pred for SOM resulted as negative value. Visualizing the hypotheses and various 
ligands in the context of the 3D-QSAR models, the Fig. 55 illustrates the most significant 
favorable and unfavorable interactions that arise when the 3D-QSAR model is applied to the 
reference ligand, chosen as the most active compound in the training set. In these 
representations, the blue cubes indicate favorable regions while red cubes indicate 
unfavorable ones for biological activity. The blue regions in the vicinity of 3′-position of the 
4’-methyl-phenyl ring of Group 2 suggested that the substitution in this area may enhance 
the activity, whereas red regions surround the para-position. 
 
 
Fig. 55: Most significant favorable and unfavorable interactions in QSAR models. 
 
The scatter plot for the training (a) and test set (b) indicates a reasonably good correlation 
between the predicted and experimental activities (Fig.56). 
The best obtained pharmacophore models were used to retrieve new potential inhibitors 
from “lead like” ZINC database (3,027,619 compounds) using virtual parallel screening. 
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Fig. 56: Scatter plots for the hA3R QSAR models applied to the training set (a) and the test set (b). Line indicates the 
hypothetical “best fit” line between the predicted and experimental values. 
 
Screening molecules were required to match all the hypotheses features. Database hits were 
ranked in order of their Fitness score, a measure of how well the aligned ligand conformer 
matches the hypothesis based on site matching, vector alignments and volume terms. As a 
result, 18189 potential ligand hits, that match with all the hypotheses, were identified. Here, 
we report the ten compounds with the best Fitness score (Table 13); the chemical structures 
of these hit molecules are presented in Fig. 57. 
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 Model Group 1 Model Group 2 Model Group 3 
ZINC ID FITNESS PRED pKi FITNESS PRED pKi FITNESS PRED pKi 
978790 2.268 7.75 1.439 7.09 1.495 6.89 
3192107 2.455 7.59 1.802 7.44 2.514 7.25 
6624316 2.458 7.80 1.695 8.00 2.536 7.37 
6624541 2.459 7.77 1.696 8.04 2.540 7.53 
8578947 2.460 7.63 1.719 7.25 2.463 7.07 
13363145 2.473 7.67 1.705 7.37 2.423 7.29 
20085946 2.493 7.60 1.696 7.41 2.577 7.03 
21774670 2.463 8.24 1.574 7.51 2.476 7.42 
21774675 2.447 7.84 1.540 7.73 2.507 7.47 
21774724 2.468 7.66 1.551 7.48 2.515 7.33 
Table 13: Fitness score of the identified lead 
 
 
Fig. 57: Chemical structures of ten compounds with the best Fitness score. 
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Therefore, these selected compounds were docked into the binding site of the modeled 
protein. The conformations of these hits bound to the modeled A3R were also analyzed to 
determine hydrogen-bonding and hydrophobic interactions. The docking results for the final 
hit molecules are given in Table 14, whereas the binding modes (structures and interacting 
residues) are shown in Fig. 58. 
 
ZINC ID FITNESS XP GSCORE 
AMINO ACIDS INVOLVED IN HYDROPHOBIC 
INTERACTIONS 
AMINO ACIDS 
INVOLVED IN H-BOND 
978790 2.518 -6.549 V72, F168, M177, L264, I268 M86 
3192107 2.455 -6.606 
V72, M86, F168, I253, V263,  
L264, I268 
 
6624316 2.458 -7.434 
V72, L89, L90, L91, M177, L246,  
I253, V259, I263, L264, I268 
T94 
6624541 2.459 -7.39 
V72, M86, F168, M177, L246, 
 I253, V263, L264 
D250 
8578947 2.46 -7.298 V72, M86, F168, I253, V263, L264 S73 
13363145 2.473 -6.927 
V72, L90, L91, M177, L246,  
I253, V259, L264, I268 
M86, L90 
20085946 2.493 -7.415 
V72, M86, L90, F168, M177,  
V259, L264, I268 
M86 
21774670 2.463 -8.427 
V72, M86, L90, L91, P168,  
M177, L246, I268 
M86, D250 
21774675 2.447 -8.461 
V72, M86, L90, L91, F168,  
M177, L246, I268 
M86 
21774724 2.468 -8.983 
V72, M86, L89, L90, L91, C166,  
F168, M177, L246, I268 
M86 
Table 14: Extra Precision (XP) Glide results for the ten lead molecules. 
 
The docked models indicate that the ligands maintain key interactions with the TM2, TM3, 
TM6 and TM7. Another important interaction with EL2 seems to be fundamental. 
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Fig. 58: Binding poses of the ten lead molecules. Hydrogen bonds are shown as dotted yellow lines. 
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The drug-like character of the lead compounds was assessed by evaluating their 
physicochemical properties using QikProp.156 Their molecular weights were <500 Da; they 
had <5 hydrogen bond donors and <10 hydrogen bond acceptors, and logP values of <5 
(Table 15). These properties are all well within the acceptable range of Lipinski’s rule of five. 
The pharmacokinetic parameters of the molecules (ADMET) showed that the partition 
coefficient (QPlogPo/w) and water solubility (QPlogS) values, which are crucial for estimating 
the absorption and distribution of drugs within the body, ranged approximately from 1.80 to 
3.32 and −5.08 to −3.56, respectively. 
 
ZINC ID MW HBD HBA QPlogPo/w QPlogS 
Percent Human 
Oral Absorption 
QPP 
Caco 
QPP 
MDCK 
978790 292.29 1 6.00 1.80 -3.62 85.55 483.06 225.31 
3192107 325.32 0 6.50 2.07 -4.25 89.99 697.98 335.40 
6624316 346.34 1 6.25 2.56 -3.58 96.61 1128.89 563.97 
6624541 348.33 0 5.50 3.32 -3.89 100.00 3874.95 3860.24 
8578947 347.37 3 5.00 2.80 -4.51 90.16 412.81 190.12 
13363145 306.32 1 6.00 2.16 -3.56 87.81 493.54 230.60 
20085946 343.34 1 7.50 2.00 -3.81 90.84 822.44 400.49 
21774670 333.34 1 6.50 2.68 -4.54 94.12 751.26 363.16 
21774675 347.37 1 6.50 3.06 -5.08 96.97 814.51 396.31 
21774724 347.37 1 6.50 2.99 -4.83 95.97 754.89 365.05 
Table 15: QikProp properties of the identified hits (MW = Molecular weight; HBD = Hydrogen bond donors by solute to 
water molecule; HBA = Hydrogen bond acceptors by solute from water molecule; QPlogPo/w = Predicted octanol/water 
partition coefficient logP; QPlogS = Predicted aqueous solubility S in mol/L; QPPCaco = Predicted apparent Caco-2 cell 
permeability in nm/sec; QPPMDC = Predicted apparent MDCK cell permeability in nm/sec) 
Thus, the pharmacokinetic parameters are well within the acceptable range defined for 
human use, thereby indicating the potential drug-likeness of these molecules. The structure 
selected by our proposed screening procedure could serve as potential specific inhibitors 
against the A3 human receptor and therefore can be proposed for therapeutic treatments of 
cancer. 
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7. Conclusions 
 
In conclusion hypoxia plays an important role in tumor progression and metastasis. Tumor 
growth leads to hypoxia, which in turn results in decreased therapeutic efficacy, stimulation 
of angiogenesis, and tumor progression. Overexpression of HIF-1α has been observed in 
many common human cancers.  
Currently, no empirical (X-ray, crystallographic) 3D structure for HIF-1α is available. In view 
of this, a protein model was constructed using homology modeling. Because the sequence 
identity between templates and the target is very low there may be significant errors. 
Regions of the model that were constructed without a template, by loop modeling, are 
generally much less accurate than the rest of the model.  
Several approaches have been used to inhibit HIF-1α expression or activity: inhibition of 
proteins that modulate HIF-1 activity, signal transduction pathways involved in HIF-1α 
activation. Selective inhibitors target protein-protein interaction, protein-DNA binding, and 
transcriptional activity, whereas non-selective ones affect downstream signaling and other 
indirect pathways. Several domains of HIF-1 might be suitable targets for the development 
of selective HIF-1 inhibitors: domains involved in the recruitment of coactivators, which are 
required for maximal transcriptional activity, or binding to DNA, which is dependent on 
sequence specificity. 
Domains of HIF-1α that mediate specific functions, such as DNA binding as well as 
transcriptional activity (C-TAD) might lead to the identification of more “selective” inhibitors. 
The identification of small molecules that inhibit the sequence-specific binding of 
transcription factors to DNA is an attractive approach for modulating HIF-1-dependent gene 
expression. The docking studies reported herein provided reliable information on the 
capability of new ligands to interact with DNA sequence.  
Another approach has been to interfere with the interaction between the C-TAD of HIF-1α 
and the CH1 domain of p300.  
The structure of the complex of the HIF-1α C-TAD with the CH1 domain of p300 is of interest 
as a potential target for design of antitumor agents. A docking study was performed on CH1 
domain with the purpose of identifing new potential inhibitors for this protein. 
Furthermore HIF-1α has been implicated to be involved in p53 stabilization. Mdm2 may act 
as a bridge and mediate the indirect interaction between HIF-1α and p53 in cells. 
Protein flexibility is an essential property of biomolecules. Thus, knowledge about flexibility 
is important for the rational design of new drugs. Although there is an abundance of 
literature available for Mdm2, no information is available concerning the lid behavior in 
apo-Mdm2. In this study, we used 35 ns MD simulations in order to analyze the different 
conformational aspects that regulate apo form and the binding of ligands in Mdm2. Starting 
from a X-ray structure of human Mdm2 presenting the lid residue, we simulated the 
behaviour in the presence of different inhibitors. To study the influence of ligands binding on 
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the Mdm2 dynamics, backbone and librational variations for bound and apo-Mdm2 were 
analyzed. Our findings suggest that the structure of the binding domain of Mdm2 adapts 
itself to the ligands. Also the N-terminal lid of Mdm2 slowly interconverts between a closed 
state and an open state which is highly flexible. While apo-Mdm2 predominantly populates 
the closed state, the binding with inhibitors shifts the equilibrium toward the open state. 
As expected different ligands could elicit different changes in structure and thus mediate a 
variety of biological functions. The in silico tools are probably able to simulate the behaviour 
of Mdm2 in the presence of any kind of ligand. A better understanding of these complex 
effects was achieved by using these computational techniques, which revealed the dynamic 
behavior of the protein-ligand complexes and the contribution of N-terminal domain 
flexibility, that has to be taken into account during the design of new inhibitors. 
Levels of both HIF-1 and adenosine are elevated within the hypoxic environment of solid 
tumors. In fact under hypoxic conditions, adenosine upregulates HIF-1α protein expression 
exclusively through the A3 receptor subtype. The new structure of hA2A solved in 2008 
provided a new starting point for homology modeling and was used as template to built 
homology model of hA3 adenosine receptor. The inclusion of an explicitly lipid bilayer into 
the energy minimisation simulation may have helped in optimising the quality of the 
structure. Our theoretical model of hA3 adenosine receptor has been used to evaluate and 
quantify the structure-activity relationship of known antagonists. Finally, the 3D-QSAR 
model has been used with the purpose of identifying new potential inhibitors for A3R. The 
identified hits seem to be both potent and specific for the desired target receptor. 
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8. Methods 
 
I-TASSER 
I-TASSER157 is an automated pipeline for protein tertiary structure prediction using multiple 
threading alignments and iterative structure assembly simulations. The target sequences are 
first threaded through a representative PDB structure library (with a pair-wise sequence 
identity cut-off of 70%) to search for the possible folds by four simple variants of Profile-
Profile threading Alignment (PPA) methods. The continuous fragments are then excised from 
the threading aligned regions which are used to reassemble full-length models while the 
threading unaligned regions (mainly loops) are built by ab initio modeling.158 
The conformational space is searched by replica-exchange Monte Carlo simulations.159 The 
structure trajectories are clustered by SPICKER160 and the cluster centroids are obtained by 
averaging the coordinates of all clustered structures. To rule out the steric clashes on the 
centroid structures and to refine the models further, we implement the fragment assembly 
simulation again, which starts from the cluster centroid of the first round simulation. Spatial 
restraints are extracted from the centroids and the PDB structures searched by the structure 
alignment program TM-align,161 which are used to guide the second round simulation. 
Finally, the structure decoys are clustered and the lowest energy structure in each cluster is 
selected, which has the Cα atoms and the side-chain centers of mass specified. Pulchra
162 is 
used to add backbone atoms (N, C, O) and Scwrl_3.0163 to build side-chain rotamers. If any 
region with >80 residues has no aligned residues in at least two strong PPA alignments of 
Z-score > Z0, the target will be judged as a multiple domain protein and domain boundaries 
are automatically assigned based on the borders of the large gaps. The final full-length 
models are generated by docking the model of domains together (Fig. 59). The domain 
docking is performed by a quick Metropolis Monte Carlo simulation where the energy is 
defined as the RMSD of domain models to the full-chain model plus the reciprocal of the 
number of steric clashes between domains. The goal of the docking is to find the domain 
orientation that is closest to the I-TASSER full-chain model but has the minimum steric 
clashes. This procedure does not influence the multiple domain proteins which have all 
domains completely aligned by the PPAs. 
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Fig. 59: I-TASSER protocol for protein structure and function prediction. 
 
GROMACS 
The GROMACS 3.1.2 package164,165 was used to perform molecular dynamics simulations, 
using the force-field parameter set 43A1. This package is a collection of programs and 
libraries for the MD simulations and subsequent analysis of trajectory data. The ligand was 
removed from the protein and 35 ns MD simulations of the free receptor were first 
performed, then 35 ns MD simulations of the Mdm2 complexed with the inhibitors were 
carried out. The systems were embedded in a water box, the simple point charge (SPC) 
water model, with margin of 9 Å between the protein and the boundaries of the periodic 
box. Chlorine counterions are added to produce a neutral charge on the system, and the 
simulations were performed in constant NPT ensemble. Lennard–Jones potentials were used 
to model the guest–host and guest–guest interactions, force calculations were truncated at 
a distance of 1.4 nm. For the calculation of long-range electrostatic forces, the particle-mesh 
Ewald (PME) method was used, with coulomb cut-off set to 0.9 nm. The temperature was 
ﬁxed at 300 K using the Berendsen thermostat and the Berendsen pressure coupling 
algorithm was used to keep the pressure constant at 300 bar. A steepest-descent energy 
minimization of the systems was first performed to relax the solute-solvent contacts and in 
order to remove bad van der Waals contacts. The second step consisted in 
position-restrained MD, restraining the atom positions of the macromolecule while letting 
the solvent move in the simulation, to soak the water molecule into the protein. Finally, the 
third step consisted of the MD simulation. The trajectory files were analysed by using 
GROMACS utilities. Moreover VEGA166 and VMD167 programs were employed for trajectory 
analysis and to manipulate the simulation snapshot structures. 
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PRINCIPLE COMPONENT ANALYSIS 
For Principle Component Analysis (PCA) a covariance matrix was constructed using the 
coordinates of all atoms from each of the 35 ns trajectories. The diagonalization of the 
covariance matrix generates a diagonal matrix of eigenvalues and a transformation matrix 
comprising eigenmodes. The modules g_covar and g_anaeig in GROMACS were used for the 
PCA calculation. The covariance matrix of the backbone atoms to a reference structure is 
diagonalized and the eigenvalues and eigenvectors are calculated. The eigenvectors of the 
covariance matrix represent the movements that have the largest impact on the overall 
movement (therefore principle components). The trajectories of the three systems were 
then projected on the first two eigenvectors, to give 2-D projections of the phase space. The 
eigenvalues revealed most of the structural changes. 
 
DESMOND 
Desmond133 is a suite of computer programs for carrying out molecular dynamics 
simulations. Such simulations model the motion of a collection of atoms — a chemical 
system — over time, according to the laws of classical physics. The chemical system exists in 
a thermodynamic environment, which represents the conditions under which the simulation 
is carried out. This environment mimics the experimental conditions: whether the 
temperature or pressure is regulated, for example, or whether the system is isolated so that 
it can not exchange energy with its environment. The chemical system occupies a 
three‐dimensional volume of space of a specified size, and each atom is generally 
represented by a particle at a specific position in that space. Motion is simulated in discrete 
time steps. From one step to the next, a tiny slice of time goes by, and atom positions 
update accordingly. The volume of space in which the simulation takes place is called the 
global cell. Desmond employs a technique known as periodic boundary conditions to wrap 
each face of the global cell to its opposite face. That is, particles that move leftwards out of 
the global cell appear to be moving in at a corresponding spot on the right‐hand face, and 
vice-versa; particles that move out the top appear to enter at the bottom, and vice‐versa; 
and finally, particles that move out the front appear at the back, and vice‐versa. 
A force field is a model of the potential energy of a chemical system. It is a set of functions 
and parameters used to model the potential energy of the system, and thereby to calculate 
the forces on each particle. To accurately simulate different kinds of systems, Desmond 
supports several variants of the Amber, CHARMM, and OPLS‐AA force field models. The 
action of the force field on the particles is described by a differential equation that Desmond 
integrates — numerically solves— at every timestep, thus computing a new position and 
velocity for every particle in the system. The differential equation is based on the laws of 
Newtonian mechanics applied to particles in the system. 
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GLIDE 
Glide124 searches for favorable interactions between one or more ligand molecules and a 
receptor molecule, usually a protein. Each ligand must be a single molecule, while the 
receptor may include more than one molecule. Glide uses a hierarchical series of filters to 
search for possible locations of the ligand in the active-site region of the receptor. The shape 
and properties of the receptor are represented on a grid by several different sets of fields 
that provide progressively more accurate scoring of the ligand poses. Conformational 
flexibility is handled in Glide by an extensive conformational search, augmented by a 
heuristic screen that rapidly eliminates unsuitable conformations, such as conformations 
that have long-range internal hydrogen bonds. Each ligand is divided into a core region and 
some number of rotamer groups. Each rotamer group is attached to the core by a rotatable 
bond, but does not contain additional rotatable bonds. During conformation generation, 
each core region is represented by a set of core conformations, the number of which 
depends on the number of rotatable bonds. For each core conformation an exhaustive 
search of possible locations and orientations is performed over the active site of the protein. 
The search begins with the selection of “site points” on an equally spaced 2 Å grid that 
covers the active site region (Fig. 60). 
 
Fig. 60: The Glide docking hierarchy. 
The second stage of the hierarchy begins by examining the placement of atoms that lie 
within a specified distance of the line drawn between the most widely separated atoms (the 
ligand diameter). Next rotation about the ligand diameter is considered, and the interactions 
of a subset consisting of all atoms capable of making hydrogen bonds or ligand-metal 
interactions with the receptor are scored (subset test). If this score is good enough, all 
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interactions with the receptor are scored. This stage is called “greedy scoring,” because the 
actual score for each atom depends not only on its position relative to the receptor but also 
on the best possible score it could get by moving ±1 Å in x, y, or z. The final step in Stage 2 is 
to re-score the top greedy-scoring poses via a “refinement” procedure, in which the ligand 
as a whole is allowed to move rigidly by ±1 Å in the Cartesian directions. Only a small 
number of the best refined poses is passed on to the third stage in the hierarchy-energy 
minimization on the pre-computed OPLS-AA van der Waals and electrostatic grids for the 
receptor. This energy minimization consists only of rigid-body translations and rotations 
when external conformations are docked. Finally, the minimized poses are re-scored using 
Schrödinger’s proprietary GlideScore scoring function. GlideScore is based on ChemScore, 
but includes a steric-clash term, adds buried polar terms devised by Schrödinger to penalize 
electrostatic mismatches, and has modifications to other terms: 
GScore = 0.065*vdW + 0.130*Coul + Lipo + Hbond + Metal + BuryP + RotB + Site 
Component Description 
vdW van der Waals energy. This term is calculated with reduced net ionic 
charges on groups with formal charges, such as metals, carboxylates, and 
guanidiniums. 
Coul Coulomb energy. This term is calculated with reduced net ionic charges on 
groups with formal charges, such as metals, carboxylates, and 
guanidiniums. 
Lipo Lipophilic contact term. Rewards favorable hydrophobic interactions. 
HBond Hydrogen-bonding term. This term is separated into differently weighted 
components that depend on whether the donor and acceptor are neutral, 
one is neutral and the other is charged, or both are charged. 
Metal Metal-binding term. Only the interactions with anionic acceptor atoms are 
included. If the net metal charge in the apo protein is positive, the 
preference for anionic ligands is included; if the net charge is zero, the 
preference is suppressed. 
BuryP Penalty for buried polar groups. 
RotB Penalty for freezing rotatable bonds. 
Site Polar interactions in the active site. Polar but non-hydrogen-bonding atoms 
in a hydrophobic region are rewarded. 
 
The choice of best-docked structure for each ligand is made using a model energy score 
(Emodel) that combines the energy grid score, the binding affinity predicted by GlideScore, 
and (for flexible docking) the internal strain energy for the model potential used to direct the 
conformational-search algorithm. This hierarchical search gives Glide exceptionally high 
accuracy in predicting the binding mode of the ligand. 
The virtual screening workflow in the Maestro graphical user interface offers the user a 
unified interface for compound database processing and the submission of a series of 
large-scale docking runs using a hierarchy of Glide docking protocols. While this is a 
straightforward example of automation, other Maestro workflows offer more novel 
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functionality: for example, induced fit docking iterates between Glide docking and Prime 
homology modelling functionality in order to incorporate some degree of protein backbone 
and sidechain refinement;168 quantum-polarised ligand docking iterates between Glide 
docking and Jaguar quantum chemical calculations in order to derive partial atomic charges 
that reflect polarisation of the ligand by the protein.169 
 
INDUCED FIT DOCKING 
The Induced Fit Protocol developed by Schrödinger, is a method for modeling the 
conformational changes induced by ligand binding. This protocol models induced fit docking 
of one or more ligands using the following steps: 
1. Constrained minimization of the receptor (Glide protein preparation, refinement 
only) with an RMSD cut off of 0.18 Å. 
2. Initial Glide docking of each ligand using a softened potential (van der Waals radii 
scaling). 
3. One round of Prime side-chain prediction for each protein/ligand complex, on 
residues within a given distance of any ligand pose (default 5 Å). 
4. Prime minimization of the same set of residues and the ligand for each protein/ligand 
complex pose. The receptor structure in each pose now reflects an induced fit to the 
ligand structure and conformation. 
5. Glide redocking of each protein/ligand complex structure within a specified energy of 
the lowest-energy structure. The ligand is now rigorously docked, using XP Glide, into 
the induced-fit receptor structure 
6. Estimation of the binding energy (IFDScore) for each output pose. 
Each complex is then ranked according to the IFD score. 
 
PHASE 
Phase153 is a versatile product for pharmacophore perception, structure alignment, activity 
prediction, and 3D database searching. Given a set of molecules with high affinity for a 
particular protein target, Phase uses fine-grained conformational sampling and a range of 
scoring techniques to identify common pharmacophore hypotheses, which convey 
characteristics of 3D chemical structures that are purported to be critical for binding. 
Pharmacophores from all conformations of the ligands in the active set are examined, and 
those pharmacophores that contain identical sets of features, with very similar spatial 
arrangements, are grouped together. If a given group is found to contain at least one 
pharmacophore from each ligand, then this group gives rise to a common pharmacophore. 
Then common pharmacophores are examined, and a scoring procedure is applied to identify 
the pharmacophore from each surviving n-dimensional box that yields the best alignment of 
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the chosen actives. This pharmacophore provides a hypothesis to explain how the active 
molecules bind to the receptor. The scoring procedure provides a ranking of the different 
hypotheses, allowing to make rational choices about which hypotheses are most appropriate 
for further investigation. If the pharmacophore is an adequate hypothesis, it should 
discriminate between active and inactive molecules. Each hypothesis is accompanied by a 
set of aligned conformations that suggest the relative manner in which the molecules are 
likely to bind. The quality of alignment is measured in three ways: (1) the alignment score, 
which is the root-mean-squared deviation in the site-point positions; (2) the vector score, 
which is the average cosine of the angles formed by corresponding pairs of vector features 
(acceptors, donors, and aromatic rings) in the aligned structures; and (3) a volume score 
based on the overlap of van der Waals models of the non-hydrogen atoms in each pair of 
structures. 
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where )(iVcommon  is the common or overlapping volume between ligand i and the reference 
ligand, while )(iVtotal  is the total volume occupied by both ligands. 
The site score, the vector score, and the volume score are combined with separate weights 
to yield a combined alignment score for each non-reference pharmacophore that has been 
aligned to the reference. Once the hypotheses have been scored on the basis of the 
alignment of the chosen actives, the score is adjusted by subtracting a multiple of the 
survival score of the inactives from the survival score of the actives.  
Finally, hypothesis may be combined with known activity data to create a 3D QSAR model 
that identifies overall aspects of molecular structure that govern activity. This model may be 
used in conjunction with the hypothesis to mine a 3D database for molecules that are most 
likely to exhibit strong activity toward the target. 
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APPENDIX 
Group 1: triazolo-quinoxaline derivatives 
 
 
 
 
Ligand R1 R2 R3 pKi 
1 NHCOCH3 H H 8,70 
2 NHCOCH3 OMe H 7,45 
3 NHCOCH3 H NH2 7,32 
4 NHCOCH3 OMe NH2 8,26 
5 NHCOPh H H 8,83 
6 NHCOPh OMe H 8,54 
7 NHCOPh NO2 H 7,00 
8 NHCOPh H NO2 7,66 
9 NHCOPh OMe NO2 6,66 
10 NHCOPh H NH2 7,66 
11 NHCOPh OMe NH2 9,00 
12 NHCOCHPh2 OMe H 7,36 
13 NHCOCHPh2 H H 9,09 
14 NHCOCHPh2 H NO2 7,83 
15 NHCOCHPh2 OMe NO2 9,10 
16 NHCOCHPh2 H NH2 8,06 
17 NHCOCHPh2 OMe NH2 8,59 
18 N(COPh)2 H H 8,28 
19 N(COPh)2 OMe H 8,48 
20 N(COPh)2 OMe NO2 6,46 
21 N(COPh)2 H NH2 5,91 
22 NHCOPh H H 8,83 
23 NHCOC6H4-4-COOMe OMe H 5,86 
24 NHCO-4-Pyridyl H H 8,21 
25 NHCO-4-Pyridyl OMe H 7,17 
26 NHSO2Ph H H 7,49 
27 NHSO2Ph OMe H 8,66 
28 NHSO2Ph H NO2 7,00 
29 NHSO2CH3 H H 5,85 
30 NHSO2CH3 OMe H 6,31 
89 
 
31 N(SO2CH3)2 H H 8,26 
32 N(SO2CH3)2 OMe H 6,41 
33 NHCONHCH2Ph H H 7,08 
34 NHCONHCH2Ph OMe H 7,19 
35 NHCONHCH2Ph H NO2 7,20 
36 NHCONHCOPh H H 5,89 
37 NHCONH-C6H4-3I H H 6,02 
38 OCH2Ph H H 7,68 
39 OCH2Ph OMe H 8,19 
40 OH NO2 H 9,22 
 
 
 
 
 
 
 
Group 2: pyrazolo-quinoline derivatives 
 
 
 
Ligand R pKi 
41 Ph 7,51 
42 C6H4-3-Me 8,30 
43 C6H4-4-Me 8,49 
44 C6H4-4-OMe 8,49 
45 C6H4-3-OMe 8,89 
46 C6H4-4-NO2 7,07 
47 CH2Ph 7,13 
 
 
 
 
 
 
 
 
90 
 
 
 
Ligand R1 R2 pKi 
48 NH2 H 6,26 
49 NH2 3-Me 7,00 
50 NH2 4-Me 6,73 
51 NH2 4-OMe 7,04 
52 NH2 3-OMe 6,64 
53 NHCOMe H 7,32 
54 NHCOMe 3-Me 7,51 
55 NHCOMe 4-Me 6,91 
56 NHCOMe 4-OMe 6,99 
57 NHCOPh H 8,68 
58 NHCOPh 3-Me 8,37 
59 NHCOPh 4-Me 8,36 
60 NHCOPh 4-OMe 8,47 
61 NHCOCH2Ph H 8,00 
62 NHCOCH2Ph 3-Me 8,41 
63 NHCOCH2Ph 4-Me 8,25 
64 NHCOCH2Ph 4-OMe 8,35 
65 NHCOCHPh2 H 8,00 
66 NHCOCHPh2 3-Me 8,41 
67 NHCOCHPh2 4-Me 8,25 
68 NHCOCHPh2 4-OMe 8,35 
69 NHCONHCH2Ph H 8,08 
70 NHCONHCH2Ph 3-Me 8,47 
71 NHCONHCH2Ph 4-Me 6,59 
72 N(COPh)2 H 8,21 
73 N(COPh)2 3-Me 7,63 
74 N(COPh)2 4-Me 7,52 
75 N(COPh)2 4-OMe 7,76 
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Group 3: annelated triazolo-pyrazine derivatives 
 
 
 
Ligand R pKi 
76 H 6,60 
77 OMe 8,48 
78 F 6,23 
 
 
 
Ligand R1 R2 pKi 
79 NH2 H 8,51 
80 NH2 OMe 6,80 
81 NH2 OH 5,87 
82 NH2 F 6,31 
83 NHC6H11 H 7,81 
84 NHC5H9 H 8,08 
85 NHCOMe H 6,86 
86 NHCOPh H 7,15 
87 NHCOCH2Ph H 7,93 
88 NHCOMe OMe 7,39 
89 NHCOPh OMe 8,34 
90 N(COPh)2 H 6,47 
91 N(COPh)2 OMe 8,11 
92 H H 6,18 
93 H OMe 7,24 
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Ligand R pKi 
94 H 6,55 
95 OMe 8,33 
 
 
 
 
 
 
Ligand R1 R2 pKi 
96 H H 8,32 
97 H OMe 7,33 
98 NHC6H11 H 6,55 
99 NHC5H9 H 6,94 
100 NHCOPh H 7,66 
101 NHCOPh OMe 6,66 
102 N(COPh)2 OMe 6,46 
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Group 4: heterocyclic derivatives  
 
 
Ligand R pKi 
103 CONHPh 8,74 
104 COCH-Ph2 9,04 
105 COPh 7,80 
106 SO2-Ph 6,13 
 
 
 
Ligand pKi 
107 7,74 
 
 
 
Ligand pKi 
108 6,20 
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Ligand R pKi 
109 NH2 7,85 
110 NHCOCH2Ph 9,19 
 
 
 
Ligand R1 R2 pKi 
111 H C6H4-4-OMe 7,06 
112 H C6H5 6,46 
113 H C6H4-4-Me 7,01 
114 H C6H4-4-Br 6,26 
115 COCH3 Ph 7,60 
116 COPh Ph 6,74 
 
 
 
Ligand R pKi 
117 C6H4-4-OMe 7,71 
118 C6H5 7,30 
119 C6H4-4-Me 7,57 
120 C6H4-4-Br 7,57 
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Ligand pKi 
121 7,27 
 
